WO2021127230A1 - Formes de tissu viables et leurs procédés de fabrication et d'utilisation - Google Patents

Formes de tissu viables et leurs procédés de fabrication et d'utilisation Download PDF

Info

Publication number
WO2021127230A1
WO2021127230A1 PCT/US2020/065688 US2020065688W WO2021127230A1 WO 2021127230 A1 WO2021127230 A1 WO 2021127230A1 US 2020065688 W US2020065688 W US 2020065688W WO 2021127230 A1 WO2021127230 A1 WO 2021127230A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
preserved
tissue sample
bone
sample
Prior art date
Application number
PCT/US2020/065688
Other languages
English (en)
Inventor
Brooke CATALFAMO
Michael Zbigniew KUBIK
Kevin Wu
Amy Ker-Ping CHANG
Eric J. Semler
Subha BHATTACHARYYA
Yen-Chen Huang
Original Assignee
Musculoskeletal Transplant Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musculoskeletal Transplant Foundation filed Critical Musculoskeletal Transplant Foundation
Priority to AU2020407094A priority Critical patent/AU2020407094A1/en
Priority to US17/784,133 priority patent/US20230044661A1/en
Priority to EP20848897.3A priority patent/EP4076557A1/fr
Priority to CA3165002A priority patent/CA3165002A1/fr
Publication of WO2021127230A1 publication Critical patent/WO2021127230A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3612—Cartilage, synovial fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3847—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Definitions

  • the present invention relates generally to preserved tissue forms which contain endogenous viable cells and retain or promote biological activity after being stored at temperatures above freezing for extended periods of time.
  • the present invention also relates to methods for making and using such preserved tissue forms.
  • tissue forms which are derived from processed tissue samples recovered from donors (either living or deceased) are known and useful as grafts for tissue repair and reconstruction in recipients having tissue which is damaged, diseased, atrophied or which could otherwise benefit from such treatment.
  • tissue form it is beneficial for the tissue form to retain or promote biological activity which facilitates tissue healing, growth and/or reconstruction.
  • biological activity may be provided by endogenous or exogenous growth factors, proteins, viable cells, or other biologically active substances present in the tissue form.
  • viable and non- viable cells and their products and components may create, participate in, or facilitate biologic signaling processes and networks which control or manage biological activity or processes. Viable cells often produce or recruit biologically active substances such as growth factors and proteins.
  • recovered tissue samples or the tissue forms produced therefrom are simply frozen by exposure to temperatures at or below about 0 °C, which is known to devitalize cells.
  • recovered tissue samples or the tissue forms produced therefrom are cryopreserved by contacting them with one or more cryopreservation agents and exposing the tissue samples or tissue forms and cryopreservation agent(s) to temperatures at or below about 0 °C.
  • Cryopreserving is known to preserve a portion of the viable cells present in the tissue sample or tissue form, but requires that the resulting tissue form be stored at temperatures at or below freezing, often at temperatures of about -30 °C or less, or even about -80 °C or less, for long term viability.
  • Cryopreserved tissue forms must also be thawed prior to implantation as grafts.
  • recovered tissue samples or the tissue forms produced therefrom are preserved by lyophilizing (i.e., freeze-drying) by contacting them with one or more lyophilizing agents and freezing them (either controlled rate or not), followed by drying under vacuum. Lyophilization is traditionally known to devitalize cells, but when viable tissues are lyophilized under appropriate conditions, it may be possible for these tissues to still retain viable cells as well as biologically active substances, such as growth factors or proteins. Lyophilized tissue forms can be stored for extended periods of time above freezing temperatures (greater than about 0 °C), but typically require rehydration prior to implantation as grafts.
  • the present invention provides a combination of particular protectants and lyopreserving techniques which produce viable tissue forms that can be stored for extended time periods above freezing of from at least 14 days to 365 days, or at least 1 year, 2 years, 3 years, or even more, while retaining a population of viable endogenous cells.
  • the present invention relates to preserved tissue forms which contain endogenous viable cells and retain or promote biological activity after being stored at temperatures above freezing for extended periods of time.
  • the present invention also relates to methods for making and using such preserved tissue forms.
  • a preserved tissue form for implanting in or on a subject which comprises a preserved tissue sample which is derived from a recovered tissue sample and contains a post-lyopreservation population of endogenous viable cells which is a portion of a pre- lyopreservation population of endogenous viable cells of the recovered tissue sample.
  • a preserved tissue form for implanting in or on a subject which comprises a preserved tissue sample which is derived from a recovered tissue sample and contains a post-lyopreservation population of endogenous viable cells which is a portion of a pre-contact population of endogenous viable cells of the recovered tissue sample.
  • a preserved tissue form for implanting in or on a subject which comprises a preserved tissue sample which is derived from a recovered tissue sample and is capable of storage at a temperature above freezing for an extended period of time, after which the preserved tissue sample contains a retained population of endogenous viable cells which is a portion of a post-lyopreservation population of endogenous viable cells.
  • the extended period of time is from 14 days to 5 years.
  • a preserved tissue form for implanting in or on a subject which comprises a preserved tissue sample comprising a tissue type, wherein, after storage at a temperature above freezing for an extended period of time, the preserved tissue sample contains a post-lyopreservation population of endogenous viable cells, wherein the post- lyopreservation population of endogenous viable cells of the preserved tissue sample is substantially comparable to a post-cryopreservation population of endogenous viable cells of a cryopreserved tissue sample which comprises the same tissue type as the preserved tissue sample.
  • the extended period of time is from 14 days to 5 years.
  • the post-lyopreservation population of endogenous viable cells of the preserved tissue sample is ⁇ 90% of the post-cryopreservation population of endogenous viable cells of the cryopreserved tissue sample.
  • the preserved tissue form of may further comprise one or more biocompatible fluids, wherein the lyopreserved tissue sample is rehydrated by contact with the one or more biocompatible fluids. After the preserved tissue sample is rehydrated and implanted in or on a subject at an implantation site, the preserved tissue form retains beneficial biological activity, promotes beneficial biological activity, or both.
  • the beneficial biological activity comprises promoting, at the implantation site, at least one of: tissue healing, tissue growth, and tissue generation.
  • a method for preparing a preserved tissue sample which comprises the steps of:
  • (D) optionally, modifying one or more of the size, shape and other physical characteristics of the tissue sample by applying one or more physical treatments, chemical treatments, or combinations thereof;
  • (F) optionally, prior to lyopreserving, storing the tissue-protectant mixture, for a period of storage time, at a storage temperature (e.g., less than -80 °C, or less than -50 °C);
  • a storage temperature e.g., less than -80 °C, or less than -50 °C
  • (G) optionally, during or after the step of (E) contacting the tissue sample with one or more protectants and prior to lyopreserving, incubating the tissue-protectant mixture at an incubation temperature, for a period of incubation time; and (H) lyopreserving the tissue-protectant mixture by first freezing the tissue-protectant mixture, and then drying the frozen tissue-protectant mixture (optionally under vacuum) to produce a preserved tissue sample having a post-lyopreservation population of endogenous viable cells, wherein the preserved tissue sample is capable of storage at a temperature above freezing for an extended period of time after which the preserved tissue sample contains a retained population of endogenous viable cells which is a portion of the post-lyopreservation population of endogenous viable cells.
  • the extended period of time is from 14 days to 5 years, such as from 14 to 150 days.
  • the one or more protectants are selected from the group consisting of: sugars, polyphenols, carotenoids, and combinations thereof.
  • the one or more protectants comprises: glucose, fructose, sucrose, trehalose, dextran, EGCG, and combinations thereof.
  • the contacting step (E) comprises contacting the tissue sample with a protectant solution comprising the one or more protectants and at least one biologically compatible fluid.
  • the incubation temperature at which the step of (G) incubating the tissue-protectant mixture prior to lyopreserving is performed, is selected from a room temperature, a refrigerating temperature, a warming temperature, and combinations thereof. In some embodiments, the incubation temperature is a refrigerating temperature comprising from about 2 °C to about 8 °C.
  • the period of incubation time, for which the step of (G) incubating the tissue- protectant mixture prior to lyopreserving is performed may be from greater than zero seconds to about 48 hours.
  • the tissue sample recovered from a donor comprises a tissue type selected from: adipose, amnion, artery, bone, cartilage, chorion, colon, dental, dermal, duodenal, endothelial, epithelial, fascial, gastrointestinal, growth plate, intervertebral disc, intestinal mucosa, intestinal serosa, ligament, liver, lung, mammary, meniscal, muscle, nerve, ovarian, parenchymal organ, pericardial, periosteal, peritoneal, placental, skin, spleen, stomach, synovial, tendon, testes, umbilical cord, urological, vascular, vein, and a combination thereof.
  • Figure 1 is a graph of the average ATP values obtained by ATP Assay testing performed on preserved cancellous bone tissue samples to confirm cell viability at 0, 4, 8, 10 and 12 weeks.
  • the term “about” means within 20%, more preferably within 10% and most preferably within 5%.
  • the term “substantial” means more than 50%, such as more than 60%, or more than 70%, preferably more than 80% or 85%, and most preferably more than 90%, or 95%, or even 98%.
  • substantially comparable means within ⁇ 90%, such as within ⁇ 85%, or within ⁇ 80%, or within ⁇ 75%, or within ⁇ 70%, or within ⁇ 65%, or within ⁇ 60%, or within ⁇ 55%, or within ⁇ 50%, or within ⁇ 45%, or within ⁇ 40%, or within ⁇ 35%, or within ⁇ 30% , or within ⁇ 25%, or within ⁇ 20%, or within ⁇ 15%, preferably within ⁇ 10%, and most preferably within ⁇ 5%, including within ⁇ any percent between 90% and 1%.
  • basal media includes any medium which maintains the viability and/or supports the growth of cells (whether isolated, cultured, resident in tissue, or otherwise positioned or adhered on a substrate) and typically comprises a carbon source (e.g., a simple sugar, such as glucose, etc.), water, various salts (such as calcium chloride, potassium chloride, magnesium sulfate, sodium chloride, etc.), amino acids, and optionally vitamins (such as thiamine, riboflavin, folic acid, etc.).
  • Suitable basal media include, without limitation, minimal essential medium (MEM), basal medium Eagle (BME), Dulbecco’s Modified Eagle’s Medium (DMEM), etc.
  • biologically compatible fluid and “biocompatible fluid” are used interchangeably herein and mean a fluid for combination with a protectant which will not produce a toxic, injurious, or immunologic response when contacted with living tissue.
  • biologically compatible fluids suitable for combination with one or more protectants include, without limitation: an aqueous buffer (for example without limitation, phosphate buffered saline (“PBS”)), a buffered or non-buffered isotonic solution (for example without limitation, an aqueous sodium chloride solution (e.g., from about 0.1 weight % (wt%) to about 1 wt%, such as about 0.9 wt%), a lactated Ringer's solution, a cell storage or culture media (for example without limitation, DMEM, a basal medium (e.g., Basal Medium Eagle (BME), or other similar media)), platelet rich plasma (PRP), lecithin, alginate, hyaluronic acid (HA), a derivative or salt of HA
  • cryopreservation means a preservation technique which avoids formation of ice crystals inside cells (whether isolated or contained in a tissue sample) during freezing by first contacting the cells, or tissue sample containing cells, with one or more cryopreservation agents which replace the water inside the cells, followed by freezing the tissue sample by reducing the temperature to 0 °C or below.
  • cryopreservation methods generally involve contacting a tissue sample recovered from a donor with one or more cryopreservation agents which means that the tissue sample contains a pre-contact population of endogenous viable cells (i.e., measured after performing all desired processing steps and prior to contacting with the cryopreservation agent(s)), and a post-contact (or pre-cry opreservation) population of endogenous viable cells (i.e., measured after performing all desired processing steps and contacting the tissue sample with one or more cryopreservation agents, but prior to cry opreserving the processed tissue sample).
  • a cryopreserved tissue sample contains a preserved TO (or “Week 0,” “post- cryopreservation”) population of endogenous viable cells.
  • a cryopreserved tissue sample will also contain a retained population of endogenous viable cells as measured after a period of storage time such as, without limitation, at least 14 days, or least 28 days, or at least 56 days, or at least 70 days, at least 90 days, at least 180 days, at least 365 days, at least 1 year, 2 years, 3 years, or any point in between, or even longer.
  • cryopreservation agents means intracellular cryoprotectants which operate by permeating the cell membrane and replacing the intracellular water to reduce the intracellular water concentration and, thereby, reduce the amount of ice formed within the cell during freezing.
  • Cryopreservation agents include, without limitation, glycols (alcohols containing at least two hydroxyl groups), such as ethylene glycol, propylene glycol, glycerol, and propanediol, as well as other compounds such as formamide, dimethylsulfoxide (DMSO), methanol, dimethyl acetamide, dimethyl formamide. It is known that intracellular cryoprotectants are often harmful and devitalize cells during performance of cryopreservation.
  • Disinfection and “disinfecting” as used herein, in all of their grammatical forms, is any process that reduces or minimizes bioburden (e.g., bacteria, fungi, etc.), viral load, or both, of an object (e.g., a tissue, a container for tissue, or an implement for processing tissue) and typically, but without limitation, involves contacting, rinsing or soaking the object with one or more disinfecting agents or a solution containing one or more disinfecting agents.
  • bioburden e.g., bacteria, fungi, etc.
  • Disinfecting agents include, any substances, molecules or other materials which accomplish disinfection including, without limitation, chlorine and chlorine compounds (e.g., hydrochloric acid), formaldehyde, glutaraldehyde, alcohols (e.g., ethanol, isopropyl alcohol), peracetic acid, surfactants (e.g., Triton X-100, Tween, Sodium Dodecyl Sulfate) combinations thereof, and solutions containing same.
  • chlorine and chlorine compounds e.g., hydrochloric acid
  • formaldehyde e.g., glutaraldehyde
  • alcohols e.g., ethanol, isopropyl alcohol
  • peracetic acid e.g., ethanol, isopropyl alcohol
  • surfactants e.g., Triton X-100, Tween, Sodium Dodecyl Sulfate
  • tissue and cells that are in a state in which they have little to no metabolic activity, but such tissue or cells have retained the ability to be returned to a state in which evidence of metabolic activity can be detected.
  • “Dormant” cells may be reinvigorated using methods such as by rehydrating with a biologically compatible fluid.
  • tissue and cells may be described as “dormant” after being subjected to a preservation method and during subsequent storage for a period of time, as described herein.
  • Endogenous refers to that which is naturally occurring, incorporated within, housed within, adherent to, attached to or resident in.
  • Exogenous refers to that which is not originally naturally present and, therefore, is introduced from or produced outside, an organism, cell, tissue, system, graft or implant. Exogenous cells, materials or substances may be derived from the same or a different individual as is intended to receive the cells, materials, substances, tissue, system, graft or implant.
  • Freeze and “freezing,” as used herein, refers to a preservation technique which involves cooling a tissue sample, with or without a preservative or preservative solution which may be present, to a temperature below the freezing temperature of the tissue sample or of the tissue sample and preservative or preservative solution and results in the formation of ice crystals within the frozen tissue sample, and sometimes within cells contained therein.
  • the aforesaid freezing temperature may be about 0 °C, or it may be less than or greater than about 0 °C, depending on the type of tissue sample and the type of preservative or preservative solution, if present.
  • a preserved tissue which has been frozen must be reconstituted by thawing.
  • Freeze-drying is synonymous and used interchangeably herein with the terms “lyophilization” and “lyophilizing” (see below).
  • a “graft” as used herein means a tissue or organ used for transplantation to, or other placement in or on, a subject (e.g., a patient). Some grafts are made from or otherwise include tissue matrices produced by processing tissue samples recovered from one or more donors.
  • the donor(s) and the receiving subject may each, independently, be: a mammal (including humans and non-human mammals), a reptile, an amphibian, fish, and/or a bird.
  • grafts include, but are not limited to, a self-tissue transferred from one body site to another in the same individual (“autologous graft”), a tissue transferred between genetically different members of the same species (“allograft”), and a tissue transferred between different species (“xenograft”).
  • autologous graft a self-tissue transferred from one body site to another in the same individual
  • allograft a tissue transferred between genetically different members of the same species
  • xenograft tissue transferred between different species
  • Lyophilization and “lyophilizing” refers to a preservation technique which involves freezing a tissue sample (either via controlled rate or not), followed by drying under vacuum, which removes ice and other frozen solvents from the frozen tissue sample through the process of sublimation and removes bound water molecules through the process of desorption.
  • the drying phase of a lyophilizing process is typically performed in two steps which include a primary drying step which removes the majority of the ice and frozen solvent (e.g., at least about 70 wt%, and often at least about 90 wt%), followed by a secondary drying step which removes additional ice and frozen solvent from the frozen tissue sample to produce a lyophilized preserved tissue having less than about 10 wt%, such as less than about 6 wt%, or even less than about 1 wt% water.
  • a primary drying step which removes the majority of the ice and frozen solvent (e.g., at least about 70 wt%, and often at least about 90 wt%)
  • secondary drying step which removes additional ice and frozen solvent from the frozen tissue sample to produce a lyophilized preserved tissue having less than about 10 wt%, such as less than about 6 wt%, or even less than about 1 wt% water.
  • “Lyophilization agents” as used herein are extracellular lyoprotectants that do not permeate the cell membrane and include: monosaccharides (e.g., glucose, sucrose), disaccharides (e.g., trehalose, lactose) and polysaccharides (e.g., dextran, hydroxyethyl starch (HES), cellulose), flavonoid polyphenols (e.g., catechins such as, without limitation, epigallocatechin gallate (EGCG), sugar alcohols (e.g., mannitol, sorbitol, xylitol, erythritol, adonitol, etc.). Combinations of these are also effective lyophilization agents.
  • monosaccharides e.g., glucose, sucrose
  • disaccharides e.g., trehalose, lactose
  • polysaccharides e.g., dextran, hydroxyethyl starch (
  • “Lyopreserving” and “lyopreservation” as used herein refer to a preservation technique which involves freezing (either via controlled rate or not) a tissue sample in the presence of one or more specific protectants or a protectant solution containing them as described herein, followed by drying under vacuum which may be performed in a single step at a constant temperature or at temperatures varied within a single range, or in two steps including a primary drying step at temperatures within a first range which removes the majority of the ice and frozen solvent (e.g., at least about 70 wt% (based on the total weight of the tissue form prior to lyopreservation), or at least about 80 wt%, or at least about 90 wt%), followed by (2) a secondary drying step at temperatures within a second range which removes additional ice and frozen solvent from the frozen tissue sample to produce a preserved tissue sample or form having less than about 15 wt% residual moisture (based on the total weight of the preserved tissue form), or having less than about 12 wt%, or less than about 10 w
  • M M
  • molarity molar concentration of a protectant or other solute in a biologically compatible fluid or other solvent in units of moles of the protectant or other solute per liter of solution (total of solute plus solvent).
  • molar concentration may be described as “millimolarity,” abbreviated as “mM,” in units of millimoles of the protectant or other solute per liter of solution (total of solute plus solvent).
  • Preservation and “preserving,” as used herein, generally means treating a tissue sample and the endogenous cells therein to minimize or prevent loss, injury, damage, decay or change and maintains or promotes viability of at least a portion of the endogenous cells.
  • preservation techniques are understood to include cryopreservation, freezing and lyophilization.
  • preservation techniques mean treatment of a tissue sample and the endogenous cells therein, with or without additional components, according to lyopreserving methods performed in the presence of one or more specific protectants or a protectant solution containing them, as described herein.
  • Protectants means substances or compounds which, when contacted with a tissue sample containing a population of viable endogenous cells, promote, facilitate, or enable the preservation of the tissue sample and cells thereof to produce a preserved tissue with at least a portion of the population of cells being viable upon reconstitution.
  • Suitable protectants include, without limitation, one or more substances selected from the group consisting of: sugars, polyphenols (i.e., flavonoids, stillbenes, lignans, phenolic acids), and carotenoids.
  • Suitable sugars include, without limitation, monosaccharides (e.g., glucose, fructose), disaccharides (e.g., trehalose) and polysaccharides (e.g., dextran).
  • Suitable flavonoid polyphenols are catechins such as, without limitation, epigallocatechin gallate (EGCG), epicatechin gallate (ECG), epigallocatechin (EGC) and epicatechin (EC).
  • Suitable carotenoids include, without limitation, a- carotene, b-carotene, b-cryptoxanthin, lycopene, lutein, and zeaxanthin.
  • One or more protectants are often, but not necessarily, provided in a protectant solution with a biologically compatible fluid.
  • Protectant solution means a mixture of at least one protectant and a biologically compatible fluid.
  • Preserved tissue sample and “preserved tissue form,” as used herein, mean a tissue sample or tissue form, respectively, which contained a population of endogenous viable cells prior to preservation and which has been subjected to a preservation technique according to the invention described and contemplated herein, which includes contacting a tissue sample with one or more preservation agents, followed by lyopreserving according to the methods described herein, such that, when reconstituted (i.e., rehydrated by contact with a biologically compatible fluid), at least a portion of the population of endogenous viable cells remains viable after preservation and storage at temperatures above freezing for an extended period of time (e.g., from at least 14 days to 365 days, or at least 1 year, 2 years, 3 years, 5 years, or even more, and including any time between 14 days and 5 years).
  • a preservation technique e.g., from at least 14 days to 365 days, or at least 1 year, 2 years, 3 years, 5 years, or even more, and including any time between 14 days and 5 years.
  • “Reconstitute” and “rehydrate” as used in connection with a preserved tissue sample or preserved tissue form comprising same mean the process by which a preserved tissue sample and cells therein are contacted with a biologically compatible fluid, which may reinvigorate dormant cells, e.g., bring cells from a dormant state to a state in which evidence of metabolic activity can be detected. Where a preserved tissue has been frozen, the preserved tissue may be thawed before, during, or after contacting with a biologically compatible fluid.
  • a preserved tissue sample or preserved tissue form may be reconstituted or rehydrated in situ, such as after being implanted in a subject, such as by bodily fluids of the subject (e.g., blood, plasma, lymphatic fluid, etc.) which are present at or recruited to the site of implantation, or with biocompatible fluid provided or added to the site of implantation (i.e., internal or external implantation site) by a medical practitioner or other user of the preserved tissue sample or preserved tissue form comprising same.
  • bodily fluids of the subject e.g., blood, plasma, lymphatic fluid, etc.
  • biocompatible fluid provided or added to the site of implantation (i.e., internal or external implantation site) by a medical practitioner or other user of the preserved tissue sample or preserved tissue form comprising same.
  • Root temperature as used herein is synonymous with ambient temperature and means from about 15 °C to about 25 °C, such as from about 19 °C to about 25 °C, or from about 20 °C to about 23 °C.
  • the term “storing,” whether used for tissue samples recovered from a donor (i.e., before or after any processing steps, including contacting with one or more protectants), or preserved tissue samples or preserved tissue forms comprising same (i.e., after lyopreserving), includes any periods of transport or shipping, regardless of temperature.
  • tissue sample and “biological tissue sample” are used interchangeably herein and mean a piece, slice, slab, section, fragment, chunk, lump, wedge, or any other shape, form or quantity, of tissue which has been recovered, harvested or otherwise derived from one or more donors, living or deceased, human or non-human, which comprises a population of viable endogenous cells and may be fresh, refrigerated (i.e., at temperatures from greater than zero to about 20 °C, or frozen (i.e., at temperatures of 0 °C or below).
  • the tissue sample may be, include, or be derived from one or more of the following tissue types: adipose, amnion, artery, bone, cartilage, chorion, colon, dental, dermal, duodenal, endothelial, epithelial, fascial, gastrointestinal, growth plate, intervertebral disc, intestinal mucosa, intestinal serosa, ligament, liver, lung, mammary, meniscal, muscle, nerve, ovarian, parenchymal organ, pericardial, periosteal, peritoneal, placental (including amnion, chorion, amnionchorion, umbilical cord, and Whartons jelly), skin, spleen, stomach, synovial, tendon, testes, umbilical cord, urological, vascular, vein, and a combination thereof.
  • the tissue is derived from a human or non-human mammal.
  • the tissue is derived from a human donor.
  • viability means having the ability to live, grow, expand or develop, or which are dormant and have potential to live, grow, expand or develop upon reconstitution (e.g., such as by thawing or rehydrating).
  • viability as applied to cells, can be characterized by having directly or indirectly observable, or measurable, metabolic activity, or which are dormant and have potential to become metabolically active upon reconstitution (e.g., such as by thawing or rehydrating).
  • compositions described and contemplated herein are preserved tissue forms comprising preserved tissue samples which are useful as grafts.
  • the preserved tissue forms comprise one or more processed tissue samples which include a population of viable cells, which are endogenous to the tissue samples and at least a portion of which remains viable after the preserved tissue samples or tissue forms comprising them are stored at temperatures above freezing for extended periods of time and then rehydrated.
  • the tissue samples are recovered from one or more donors and then processed with one or more processing steps and techniques which include contacting the tissue samples with one or more protectants, and lyopreserving the resulting tissue-protectant mixture (which may also be described as lyopreserving a tissue sample in the presence of one or more protectants or a protectant solution).
  • the population of viable cells comprise cells endogenous to at least one of the processed tissue samples included in the tissue form.
  • the population of viable cells may be supplemented or combined with exogenous viable cells, which may be autogenic, allogenic, xenogenic, or combinations thereof.
  • the preserved tissue sample comprises a population of endogenous viable cells at least a substantial portion (i.e., at least 98 %, or at least 90 %, or at least 80 %, etc.) of which remain viable after convenient storage of the preserved tissue forms at temperatures above freezing (i.e., greater than 0 °C), for extended periods of time (e.g., up to 14 days, or up to 90 days, or up to 180 days, or up to 365 days, or at least 1 year, 2 years, 3 years, 5 years, or even longer, and including any time between 14 days and 5 years).
  • extended periods of time e.g., up to 14 days, or up to 90 days, or up to 180 days, or up to 365 days, or at least 1 year, 2 years, 3 years, 5 years, or even longer, and including any time between 14 days and 5 years).
  • tissue forms avoid (1) safety issues sometimes presented by exposure to ultra-low temperatures (i.e., less than about -50 °C) and (2) the inconvenient necessity for thawing the preserved tissue form before use, both of which are encountered when using cryopreserved tissue forms.
  • the preserved tissue forms described and contemplated herein are useful for tissue repair and reconstruction in recipients having tissue which is damaged, diseased, atrophied or which could otherwise benefit from such treatment (including structural, functional and aesthetic benefits).
  • the preserved tissue forms are useful for tissue repair and reconstruction, at least in part, because the endogenous viable cells retain and/or promote biological activity which facilitates tissue healing, growth and/or generation. Without intending to be limited by theory, it is believed that such biological activity may be provided by the endogenous viable cells themselves and/or growth factors, proteins, or other biologically active substances secreted by, or recruited from surrounding tissue by, the viable cells, or both. This biological activity is in addition to any such activity which may be provided by any growth factors, proteins or other substances already present and remaining in the tissue samples during and after processing.
  • viable cells such as, without limitation, mesenchymal stem cells (MSCs), which are contained in several types of tissue samples (e.g., without limitation, bone, bone marrow, adipose, placenta, etc.) both before and after being subjected to the lyopreserving method described and contemplated herein, are known to secrete several types of biologically active substances including growth factors, cytokines, chemokines, and other proteins which cause or contribute to paracrine effects (immunomodulatory, anti-apoptotic, supportive (e.g., stimulation of mitosis, proliferation and differentiation), angiogenic, anti-scaring, chemoattractant, etc.) known to enhance wound healing and tissue reconstruction.
  • MSCs mesenchymal stem cells
  • VEGF vascular endothelial growth factor
  • HGF hepatocyte growth factor
  • IGF-1 insulin-like growth factor-1
  • plGF placental growth factor
  • TGF-b transforming growth factor beta
  • bFGF basic fibroblast growth factor
  • GM- CSF granulocyte-macrophage colony-stimulating factor
  • PGE-2 prostaglandin E2
  • IDO indoleamine 2,3-dioxygenase
  • IL interleukin
  • IL interleukin
  • IL-1 receptor antagonist IL-1 receptor antagonist
  • TNF-a tumor necrosis factor alpha
  • TNF-a monocyte chemoattractant protein- 1
  • MCP-1 / also known as CCL2 macrophage inflammatory proteins
  • preserved tissue forms contain both paracrine signaling substances (growth factors, cytokines, chemokines, etc.) already secreted by endogenous viable cells of the tissue sample (before and during lyopreserving), as well as viable cells which continue to secrete such paracrine signaling substances after lyopreserving and rehydration.
  • paracrine signaling substances growth factors, cytokines, chemokines, etc.
  • preserved tissue samples and preserved tissue forms comprising them which are produced in accordance with the lyopreserving methods described and contemplated herein, upon rehydration, behave and function as conditioned media containing biologically active substances which cause or contribute to paracrine effects and other beneficial biological activities which cause, facilitate or enhance wound healing and tissue reconstruction when implanted in a host, patient or subject.
  • preserved tissue samples and preserved tissue forms comprising them upon rehydration, also produce and provide additional quantities of biologically active substances which continue to provide such beneficial healing and reconstructive activity at the site of implantation.
  • the site of implantation may be within or on an external surface of a subject, or a combination or both.
  • the recovered tissue samples may be, include, or be derived from one or more of the following tissue types: adipose, amnion, artery, bone, cartilage, chorion, colon, dental, dermal, duodenal, endothelial, epithelial, fascial, gastrointestinal, growth plate, intervertebral disc, intestinal mucosa, intestinal serosa, ligament, liver, lung, mammary, meniscal, muscle, nerve, ovarian, parenchymal organ, pericardial, periosteal, peritoneal, placental (including amnion, chorion, amnionchorion, umbilical cord, and Wharton’s jelly), skin, spleen, stomach, synovial, tendon, testes, umbilical cord, urological, vascular, vein, and a combination thereof.
  • tissue types adipose, amnion, artery, bone, cartilage, chorion, colon, dental, dermal, duodenal
  • tissue types include, without limitation: adipose, fascia, dermis, bone, cartilage, muscle, placenta (including amnion, chorion, amniochorion, Wharton’s jelly, and umbilical cord), placental disk, and combinations thereof.
  • embodiments of the present invention include preserved tissue forms comprising at least one processed tissue sample which has been contacted with one or more protectants and lyopreserved (i.e., at least one preserved tissue sample), methods for producing such preserved tissue forms, and methods for using such preserved tissue forms.
  • tissue samples comprising bone (e.g., cancellous bone), cartilage, and placental (e.g., amnion and chorion) tissues
  • placental e.g., amnion and chorion
  • the present invention contemplates and includes embodiments comprising more than one tissue type and that those tissue types may be processed the same way or differently. Additionally, the present invention contemplates and includes embodiments in which the preserved tissue form further comprises materials, substances or components, which may be natural or synthetic, in addition to one or more processed tissue samples at least one of which has been contacted with one or more protectants and lyopreserved. All such embodiments, and other reasonably overlapping or derived from those described herein are within the scope of the present invention.
  • the one or more preserved tissue samples included in any particular preserved tissue form may be autografts (i.e., recovered from the same individual donor as the intended recipient), allografts (i.e., recovered from a different individual donor of the same species as the intended recipient), xenografts (i.e., recovered from an individual donor of a different species as the intended recipient), or combinations thereof.
  • the tissue samples are processed by applying steps and techniques which are selected depending on the type of tissue recovered, the desired characteristics of the processed tissue samples, the intended tissue form and its intended use (i.e., the particular intended recipient, the tissue type to be treated, the condition to be treated and the desired results of said treatment).
  • the method for producing a preserved tissue form comprises processing a tissue sample by performing one or more of the following steps:
  • (D) optionally, modifying one or more of the size, shape and other physical characteristics of the tissue sample by applying one or more physical treatments, chemical treatments, or combinations thereof;
  • (F) optionally, prior to lyopreserving, storing the tissue-protectant mixture, for a period of storage time, at a storage temperature (e.g., less than -80 °C, or less than -50 °C), optionally in contact with storage media, preservatives, priming media, or combinations thereof; (G) optionally, prior to ly opreserving, incubating the tissue-protectant mixture at an incubation temperature, for a period of incubation time, optionally in contact with storage media, preservatives, priming media, or combinations thereof;
  • a storage temperature e.g., less than -80 °C, or less than -50 °C
  • (H) lyopreserving the tissue-protectant mixture by first freezing the tissue-protectant mixture, and then drying the frozen tissue-protectant mixture (optionally under vacuum) to produce a processed (lyopreserved) tissue sample.
  • the resulting processed tissue sample is a lyopreserved tissue sample which may, by itself, be suitably useful as a preserved tissue form and implanted into a subject.
  • the method for producing a preserved tissue form may further comprise combining the processed preserved tissue sample with one or more additional components, either prior to, during or after the lyopreserving step (H).
  • the tissue sample After recovery or harvest of the tissue sample from one or more donors, the tissue sample includes a fresh population of viable cells which are endogenous to the tissue sample.
  • the processed tissue sample Before performing the step of contacting (E) the tissue sample with one or more protectants, but after all other desired processing steps are performed, the processed tissue sample includes a pre-contact (or Baseline) population of viable cells which is at least a portion of the fresh population of viable cells.
  • the processed tissue form includes a post-contact (or pre- lyopreservation / “pre-lyo”) population of viable cells which is at least a portion of the pre-contact population of viable cells.
  • the resulting preserved tissue form (with or without one or more additional components, in addition to the preserved tissue sample) includes a preserved TO (or “Week 0,” “post-lyopreservation,” or “post-lyo”) population of viable cells which is at least a portion of the post-contact population of viable cells.
  • the TO (“Week 0,” “post-lyopreservation,” or “post-lyo”) population of viable cells should be measured shortly after the lyopreserving step (H) is completed, such as within about 7 days, or within about 96 hours, or within about 48 hours, or even within about 24 hours, of completing the lyopreserving step (H).
  • the preserved tissue form may be stored at temperatures above freezing, for an extended period of time, after which the preserved tissue form includes a retained population of viable cells, which is at least a portion of the TO population of viable cells.
  • the fresh, pre-contact (“Baseline”), post-contact (pre- lyopreservation, or pre-lyo), TO (“Week 0,” “post-lyopreservation,” or “post-lyo”), and retained populations of viable cells each comprise viable cells endogenous to at least one tissue sample which has been subjected to processing as described and contemplated herein to produce the preserved tissue form.
  • the viable endogenous cells of a preserved tissue sample are those which were present in the original unprocessed tissue sample and have not been removed from that tissue sample during processing and lyopreserving.
  • one or more of the fresh, pre contact (“Baseline”), post-contact (pre-lyopreservation, or pre-lyo), TO (“Week 0,” “post- lyopreservation,” or “post-lyo”), and retained populations of viable cells may each be supplemented or combined with exogenous viable cells, which may be, independently of one another, autogeneic, allogeneic, xenogeneic, or combinations thereof, and may have been added to the tissue form at any point during the processing and preservation steps.
  • the retained population of viable cells is more than 50% of the TO population of viable cells, such as more than 60%, or more than 70%, preferably more than 80% or 85%, and most preferably more than 90%, or 95%, or even 98%.
  • Storage of the preserved tissue form at temperatures above freezing includes, for example without limitation, storage at room temperatures (i.e., from about 19 °C to about 25 °C), or refrigeration temperatures (i.e., from greater than 0 °C to about 10 °C), or intermediate temperatures (i.e., from greater than 10 °C to less than about 19 °C).
  • Extended periods of time for which preserved tissue forms may be stored and still have a retained population of viable cells includes, for example without limitation, from at least 14 days to 365 days or more, such as at least 14 days, or at least 28 days, or at least 56 days, or at least 70 days, or at least 90 days, or at least 180 days, or at least 270 days, or at least 365 days, or at least 1 year, 2 years, 3 years, or even longer, and including any time between 14 days and 5 years.
  • periods of storage may include or overlap with one or more periods of time during which the preserved tissue sample or preserved tissue form comprising same is transported or shipped from one location to another, and during at least a portion of which the temperature to which the preserved tissue sample or preserved tissue form comprising same is exposed may be at or below freezing, or above freezing.
  • the preserved tissue form provides several benefits and advantages, including but not limited to: (1) providing a preserved tissue form containing a (retained) population of viable cells which may be conveniently stored at temperatures above freezing until use, (2) resolving customer safety concerns presented by exposure to ultra-low temperatures (e.g., below -50 °C or even -80 °C) relative to conventional cryopreserved tissue forms, and (3) eliminates the need for thawing time prior to use as compared to conventional cryopreserved and frozen tissue forms.
  • the ability to store the tissue forms above freezing temperature eliminates the need for costly storage resources (dry ice, liquid nitrogen, tanks and freezers, etc.) and removes certain limitations on tissue shipment (limit on shipment time and size due to dry ice).
  • Tissue samples are recovered from a donor (A) according to accepted ethical and sterile procedures, which involve donor screening, obtaining donor releases and informed consent, tissue screening and testing and tissue transport to facilities for further processing.
  • the tissue samples may be stored, such as in a biologically compatible fluid or not, for a period of time after recovery from the donor(s) (A) and prior to shipping / transport, or during shipping / transport, or even for a period of time after arriving at a processing facility but prior to commencement of processing steps (e.g., cleaning (B), disinfecting (C), modifying the size, shape, or other physical characteristics (D), contacting with one or more protectants (E), storing (F), incubating (G), lyopreserving (H), etc.).
  • cleaning cleaning
  • C disinfecting
  • D modifying the size, shape, or other physical characteristics
  • E contacting with one or more protectants
  • G incubating
  • H lyopreserving
  • recovered tissue samples may be held or stored in another kind of solution, such as, without limitation, a red cell lysis buffer such as ACK (Ammonium-Chloride-Potassium) Lysing Buffer which is intended to facilitate removing unwanted blood from the samples.
  • a red cell lysis buffer such as ACK (Ammonium-Chloride-Potassium) Lysing Buffer which is intended to facilitate removing unwanted blood from the samples.
  • the step of cleaning (B) a recovered tissue sample is typically intended to isolate the desired tissue type by removing unwanted tissue and other materials and may, for example, include one or more of the following processes: (1) debriding or otherwise separating the recovered tissue sample to remove and separate unwanted tissue from desired recovered tissue; and (2) removing unwanted materials and substances including, without limitation, blood, lipids, debris, and unwanted tissue by rinsing or washing the recovered tissue sample, for a period of cleaning time, at least once, with one or more fluids such as, without limitation, buffered or unbuffered saline solution, lactated Ringer’s solution, balanced salt solution, basal medium, water, or combinations thereof.
  • one or more fluids such as, without limitation, buffered or unbuffered saline solution, lactated Ringer’s solution, balanced salt solution, basal medium, water, or combinations thereof.
  • a suitable period of cleaning time for rinsing or washing during the step of cleaning (B) the tissue sample is typically, for example without limitation, at least 2 seconds, or at least 10 minutes, or at least 20 minutes, or from about 2 seconds to about 2 hours, such as from about 2 seconds to about 5 minutes, or from about 5 minutes to about 20 minutes, or from about 20 minutes to about 2 hours.
  • the step of (B)(2) removing unwanted materials and substances from a recovered tissue sample may also, or alternatively, be performed by contacting the recovered tissue sample with supercritical carbon dioxide for a period of time of from about 2 minutes to about 60 minutes, such as from about 5 minutes to about 60 minutes, or from about 5 minutes to about 40 minutes, or from about 5 minutes to about 30 minutes, or from about 5 minutes to about 20 minutes.
  • the step of disinfecting (C) a recovered tissue sample typically, but without limitation, includes contacting, rinsing, or soaking the tissue sample, for a period of disinfecting time, with one or more disinfecting agents or a disinfecting solution comprising one or more disinfecting agents.
  • a suitable period of disinfecting time for the step of disinfecting (C) will depend on the type and concentration of disinfecting agent or disinfecting solution and is typically, for example without limitation, at least 0.5 seconds, or from about 0.5 seconds to about 2 hours, such as from about 0.5 seconds to about 5 minutes, or from about 5 minutes to about 20 minutes, or from about 20 minutes to about 2 hours, or from about 30 minutes to about 2 hours, or from about 30 minutes to about 1.5 hours, or from about 30 minutes to about 1 hour.
  • Suitable disinfecting agents include, without limitation, chlorine and chlorine compounds (e.g., hydrochloric acid), alcohols (e.g., ethanol, isopropyl alcohol), peracetic acid, surfactants (e.g., Triton X-100, Tween, Sodium Dodecyl Sulfate), antibiotics (e.g., amoxicillin, penicillin, gentamicin, amphotericin, doxycycline, azithromycin, vancomycin, etc.), antimycotics (e.g., amphotericin B, nystatin), combinations thereof, and solutions containing same.
  • chlorine and chlorine compounds e.g., hydrochloric acid
  • alcohols e.g., ethanol, isopropyl alcohol
  • peracetic acid e.g., surfactants (e.g., Triton X-100, Tween, Sodium Dodecyl Sulfate)
  • antibiotics e.g., amoxicillin
  • the step of disinfecting (C) comprises soaking the tissue sample in a sufficient volume of peracetic acid solution for a sufficient amount of disinfecting time so as to produce a disinfected tissue sample, wherein the disinfected tissue sample has a sterility assurance level of at least 10 6 .
  • the sterility of the disinfected tissue sample is determined by the method described in International Standards ISO 14937:2009.
  • a sufficient volume of peracetic acid would provide, for example without limitation, a ratio of the tissue sample surface area (cm 2 ) to the volume of peracetic acid solution (ml) of from about 0.01 cm 2 /ml to about 0.65 cm 2 /ml.
  • the step (D) of modifying size or shape of the tissue sample includes, without limitation, increases or decreases in one or more dimensions (e.g., without limitation, changes to one of more of diameter, width, length, height, thickness, etc.) and formation or molding recovered tissue into any desired shape, whether by manual manipulation or with the use of a container or mold.
  • Possible shapes for the tissue samples, processed tissue samples, and preserved tissue forms include, without limitation, particles, strips, chunks, pieces, blocks, sheets, slivers, ribbons, branched and unbranched elongated elements, filaments, fibers, three dimensional geometric shapes such as symmetric and asymmetric spheres, regular and irregular polyhedrons, cones, pyramids, other three dimensional forms having one or more planar or curved surfaces, and irregular three dimensional forms.
  • processed tissue samples and preserved tissue forms comprising them may be produced in the form (i.e., have the shape) of, for example without limitation, one or more of particulates, fibers, chunks or pieces, etc.
  • a first shape i.e., a first shape
  • another desired shape for example without limitation, sheets, blocks, cylinders, plugs or other three-dimensional shape (i.e., a second shape)
  • Modifications to other physical characteristics include, without limitation, removal of lipids such as for adipose tissue, demineralizing such as for bone tissue, changes to the molecular structure of collagens or proteins in a tissue sample (e.g., digestion, hydrolysis, cleavage, crosslinking, etc.), and increasing or decreasing flexibility, density, compressibility, elasticity, etc.
  • the optional step (D) of modifying size, shape or other physical characteristics of the tissue sample includes, for example without limitation, one or more of the following physical processes: cutting, slicing, cleaving, chopping, grating, grinding, milling, fragmenting, blending, homogenizing, extruding, fracturing, separating, pressing, molding, manual manipulation, heating, cooling, freezing, and the like, using devices known now or in the future to persons of ordinary skill in the relevant art.
  • Selection of a physical process and a device for performing the selected physical process is within the ability of persons of ordinary skill in the relevant art based on this disclosure and the knowledge generally possessed by and available to such persons and will depend on various factors including, without limitation, the type of tissue sample being treated, the condition intended to be treated by the resulting tissue form comprising the processed tissue sample, and the desired result of such treatment.
  • the step (D) of modifying size, shape or other physical characteristics of the recovered tissue sample includes, for example without limitation, one or more of the following chemical processes: digesting, cleaving, dissolving, disintegrate, dissociating, hydrolyzing, fragmenting, separating, extracting, absorbing, desorbing, aggregating, linking, and the like, using agents and techniques known now or in the future to persons of ordinary skill in the relevant art.
  • Suitable agents and techniques include, for example without limitation, contacting the tissue sample with an enzyme (e.g., a kinase, an amylase, telomerase, trypsin, collagenase, pepsin, lipase, etc.), an acid, abase, an ionic substance, a surfactant, and the like, and combinations thereof, with or without heating or cooling for a period of time sufficient to accomplish the desired degree of chemical alteration of the tissue sample.
  • an enzyme e.g., a kinase, an amylase, telomerase, trypsin, collagenase, pepsin, lipase, etc.
  • any combination of one or more physical and chemical processes may be performed, in any order, to accomplish the step (D) of modifying size, shape or other physical characteristics of the tissue sample.
  • more than one physical process may be performed.
  • more than one chemical process may be performed.
  • the step (D) of modifying size, shape or other physical characteristics of the tissue sample may include at least one physical process and at least one chemical process.
  • one or more chemical processes may be performed prior to any physical processes, and in other embodiments, one or more physical processes may be performed prior to any chemical processes.
  • one or more chemical processes may be performed both prior to and after one or more physical processes.
  • one or more physical processes may be performed both prior to and after one or more chemical processes.
  • the physical and chemical processes of step (D) may be performed in any order as desired.
  • the steps of cleaning (B), disinfecting (C), and modifying one or more of the size, shape and other physical characteristics of (D) the tissue sample may each be performed with one or more repetitions and in any order, at the discretion of persons of ordinary skill. For example, without limitation, these steps may be performed sequentially as listed above.
  • a recovered tissue sample may first be disinfected (C) and then cleaned (B), with or without subsequent modifying one or more physical characteristics (D).
  • a recovered tissue sample may be cleaned (B), disinfected (C), then cleaned again (B), prior to, optionally, modifying one or more physical characteristics (D).
  • a recovered tissue sample may be cleaned (B), then cleaned (B) again (such as with different cleaning agents or by different cleaning techniques, etc.), followed by disinfecting (C), with or without subsequent modifying one or more physical characteristics (D).
  • a tissue sample may be subjected to a step of modifying one or more of its physical characteristics (D), followed by one or more cleaning steps (B), then further modifying one or more of physical characteristics (D) of the tissue sample, followed by disinfecting (C), and then an additional cleaning step (B).
  • any such number and order of the optional steps of cleaning (B), disinfecting (C), and modifying one or more physical characteristics (D), as well as other arrangements of such steps, are possible and suitable, as is within the ability of persons of ordinary skill in the relevant art to determine, depending on the source, type and intended use of the recovered tissue.
  • the tissue sample is contacted, in step (E) listed above, with one or more protectants (in solution or not) for a period of contacting time to form a tissue-protectant mixture comprising a quantity of tissue sample and the one or more protectants.
  • the period of contacting time is from greater than zero seconds and extends until ly opreserving is commenced, such as up to about 48 hours.
  • the period of contacting time for the step of (E) contacting the tissue sample with one or more protectants may be at least about 10 minutes, or at least about 15 minutes, or at least about 20 minutes, or at least about 60 minutes, or at least about 120 minutes, or at least about 180 seconds, or at least 240 minutes, or at least 6 hours, or at least 10 hours, or any value from greater than zero to about 48 hours.
  • the tissue sample or portions thereof may be contacted with (e.g., rinsed, soaked, stored in, etc.) one or more protectants (in solution or not) at any time during processing, before during or after any of the steps of the method for producing the preserved tissue forms described herein.
  • any periods of time for which the tissue sample or portions thereof is contacted with one or more protectants before or during any of the steps of (A) recovering, (B) cleaning, (C) disinfecting, (D) modifying, (E) storing or (F) incubating, the tissue sample are not necessarily intended to be included in the period of contacting time which occurs during the contacting step (E) performed prior to lyopreserving as discussed above.
  • the tissue sample or a portion thereof may be contacted with one or more protectants (in solution or not) for a period of time longer than about 48 hours, particularly, when the contact also occurs before or concurrently with one or more of the steps performed prior to the step of (H) lyopreserving.
  • the period of contacting time may, without limitation, be at least about 20 minutes, or at least about 30 minutes, or at least about 60 minutes, or at least about 120 minutes, or at least about 180 minutes, or at least 240 minutes, or any value between greater than zero and up to about 6 hours, or up to about 7 hours, or up to about 8 hours, or even up to about 9 hours.
  • the period of contacting time may, without limitation, be at least about 10 minutes, or at least about 30 minutes, or at least about 60 minutes, or at least about 120 minutes, or at least about 180 minutes, or at least 240 minutes, or at least 300 minutes, or any value between greater than zero and up to about 6 hours, or up to about 7 hours, or up to about 8 hours, or even up to about 9 hours.
  • the period of contacting time may, without limitation, be at least about 15 minutes, or at least about 30 minutes, or at least about 60 minutes, or at least about 120 minutes, or at least about 180 minutes, or at least 200 minutes, or any value between greater than zero and up to about 4 hours, or up to about 5 hours, or up to about 6 hours, or up to about 7 hours, or up to about 8 hours, or even up to about 9 hours.
  • protectants suitable for use with the method described herein include, without limitation, one or more of: low molecular weight non-reducing sugars (e.g., trehalose, sucrose, glucose, etc.), dextran, catechins (e.g., epigallocatechin (EGG), epigallocatechin gallate (EGCG), etc.), carotenoids (a-carotene, b-carotene, b-cryptoxanthin, lycopene, lutein, zeaxanthin, and other naturally occurring carotenoids), glycerol, antioxidants (e.g., ascorbic acid (vitamin C), vitamin E, etc.), and late embryogenesis abundant (LEA) proteins.
  • Preferred protectants include trehalose, EGCG, and combinations thereof.
  • EGCG is also known to have antioxidant properties and, therefore, is a highly suitable protectant.
  • the protectants may be contacted with the tissue sample in any order and combination.
  • a first protectant may be contacted with the tissue sample, and then an additional one or more (i.e., second, third, fourth, etc.) protectants may be added sequentially, or in combinations.
  • two or more protectants may be contacted with the tissue sample concurrently, either by separate but concurrent addition to the tissue sample, or by mixing the protectants together and then adding the mixed protectants to the tissue sample.
  • two or more protectants may be combined with one another to form a first protectant mixture, and two or more different protectants may be combined with one another to form a first protectant mixture, and then the first and second protectant mixtures added to the tissue sample, separately but concurrently, or sequentially, or by first mixing the first and second protectants mixtures together and then adding the resulting combined mixtures to the tissue sample.
  • the one or more protectants will typically, but do not have to, be in solution with a biologically compatible fluid.
  • suitable biologically compatible fluids include, for example without limitation, one or more of: saline, PBS, Hank’s balanced salt solution (HBSS), Hy clone ® growth media containing fetal bovine serum (commercially available from Thermo Fisher Scientific of Carlsbad, California, U.S.A.), Dulbecco's Modified Eagle's medium (DMEM), Basal Medium Eagle (BME), and derivatives and combinations thereof.
  • the solution may be sterilized, such as by exposure to ultraviolet or gamma radiation, filtering through a filter, such as a 0.2 um filter, or other techniques known to persons of ordinary skill in the art and discussed further hereinbelow.
  • the protectant solution comprises trehalose and EGCG dissolved in PBS.
  • trehalose is at least one of the protectants in the protectant solution
  • trehalose may, for example, be present in a concentration of from about 0.1 M to about 1 M, such as from about 0.2 M to about 0.6 M, or from about 0.3 M to about 0.5 M, or about 0.4 M, or about 0.5 M.
  • EGCG is at least one of the protectants in the protectant solution
  • EGCG may, for example, be present in a concentration of from about 0.5 mM to about 8 mM, such as from about 1 mM to about 6 mM, or from about 3 mM to about 5 mM, or about 4 mM.
  • additional ingredients may be combined with the protectant(s) or the protectant solution.
  • suitable additional ingredients for the protectant solution include, without limitation, one or more of: nonionic surfactants (e.g., Polysorbate 80), glucose, mannitol, amino acids (e.g., glycine), salts, vitamins, human serum albumin (HSA), bovine serum albumin (BSA).
  • an exemplary protectant solution comprises trehalose and EGCG dissolved in either Hyclone® media or phosphate buffered solution (PBS) at a concentration of from about 0.1 to about 0.5M and from about 1.0 to about 4.0mM, respectively.
  • the protectant solution may comprise IX PBS, 0.4M trehalose and 4.0 mM EGCG.
  • the aforesaid exemplary protectant solutions further comprise dextran, glycerol, or a combination of both.
  • the step (E) of contacting the tissue sample with one or more protectants may be performed at room temperature (i.e., from about 19 °C to about 25 °C) and ambient pressure (typically from about 0.8 atmosphere (atm) to about 1.05 atm, which is from about 85 kilopascals (kPa) to about 107 kPa, depending on altitude).
  • the tissue sample is contacted with one or more protectants and subjected to heating (e.g., application of or exposure to one or more temperatures above about 25 °C) or cooling (e.g., application of or exposure to one or more temperatures below about 19 °C), for all or a portion of the contacting time.
  • the resulting tissue-protectant mixture is subjected to the step of (H) ly opreserving.
  • the tissue-protectant mixture may be subjected to one or more other intermediate treatment (i.e., processing) steps, such as one or more of cleaning (B), disinfecting (C), and modifying one or more of the size, shape and other physical characteristics (D), at the discretion of persons of ordinary skill.
  • the tissue-protectant mixture may be soaked or rinsed with a biocompatible fluid (e.g., PBS, a culture media, a buffered isotonic solution, etc.), or even with a second protectant solution (either of the same composition already used, or different composition), prior to performing a lyopreserving step (H).
  • a biocompatible fluid e.g., PBS, a culture media, a buffered isotonic solution, etc.
  • a second protectant solution either of the same composition already used, or different composition
  • the step (H) of lyopreserving the tissue-protectant mixture is typically performed by first freezing the tissue-protectant mixture, and then drying the frozen tissue-protectant mixture under vacuum to produce a processed tissue sample which has a retained population of viable cells after rehydration.
  • the freezing phase of the lyopreserving step (H) may, for example without limitation, be performed at one or more temperatures in a range of from about -80 °C to about -4 °C, such as from about -70 °C to about -4 °C, or from about -50 °C to about -4 °C. In some embodiments, the freezing phase of the lyopreserving step (H) is performed at a rate of from about 0.1 °C/minute to about 10 °C/minute, such as from about 0.1 °C/minute to about 5 °C/minute, or from about 0.1 °C/minute to about 2 °C/minute.
  • the freezing phase of the lyopreserving step (H) may be performed over a total freezing time of from about 5 minutes to about 300 minutes, or any range therebetween, such as without limitation from about 5 minutes to about 200 minutes, or from about 5 minutes to about 250 minutes, or from about 5 minutes to about 180 minutes, or from about 5 minutes to about 130 minutes, or from about 5 minutes to about 100 minutes, or from about 5 minutes to about 90 minutes, or from about 5 minutes to about 75 minutes, or from about 5 minutes to about 60 minutes, or from about 5 minutes to about 30 minutes, or from about 10 minutes to about 300 minutes, or from about 15 minutes to about 200 minutes, or from about 20 minutes to about 300 minutes, or from about 30 minutes to about 300 minutes, or from about 30 minutes to about 300 minutes, or from about 45 minutes to about 300 minutes, or from about 60 minutes to about 300 minutes, or from about 75 minutes to about 300 minutes, or from about 90 minutes to about 300 minutes, or from about 90 minutes to about 180 minutes, or from about 90 minutes to about 135 minutes.
  • the drying phase of the lyopreserving step (H) removes water and other solvents from the frozen tissue sample and is performed for a period of total drying time.
  • the drying phase of the lyopreserving step (H) is performed under vacuum in a single step, either at a constant temperature or at varied temperatures (e.g., two or more steps) within a single range.
  • the drying phase of the lyopreserving step (H) is performed, under vacuum or not, in two steps including a primary drying step at one or more temperatures within a first range which removes the majority of the ice and frozen solvent (e.g., at least about 70 wt% of the frozen water is removed), followed by (2) a secondary drying step at one or more temperatures within a second range which removes additional ice and frozen solvent from the frozen tissue sample to produce a preserved tissue sample having less than about 10 wt% water.
  • the drying phase of the lyopreserving step (H) is performed in three or more steps, analogous to those described above.
  • ranges of temperatures employed during the one or more steps of the drying phase may overlap or not.
  • controlled rate lyopreserving may be desired because it tends to avoid changes in the dried product appearance and characteristics.
  • the drying phase may, for example without limitation, be performed at a pressure of from about 0.013 kPa to about 0.13 kPa (i.e., from about 100 milliTorr (mTorr) to about 1000 mTorr), for example from about 0.013 kPa to about 0.1 kPa (i.e., from about 100 mTorr to about 750 mTorr), or from about 0.013 kPa to about 0.066 kPa (i.e., from about 100 mTorr to about 500 mTorr).
  • mTorr milliTorr
  • 0.1 kPa i.e., from about 100 mTorr to about 750 mTorr
  • 0.013 kPa to about 0.066 kPa i.e., from about 100 mTorr to about 500 mTorr.
  • the vacuum and pressure during the drying phase of the lyopreserving step (H) need not remain constant throughout the drying phase.
  • the vacuum and pressure during the drying phase varies, by gradual change rates or by step changes, in a range of from about 0.013 kPa to about 0.13 kPa (i.e., from about 100 mTorr to about 1000 mTorr), with possible exemplary sub ranges as stated above.
  • the total drying time for which the drying phase of the lyopreserving step (H) is performed may, for example without limitation, be up to about 48 hours, or from about 2 hours to about 48 hours, or any range therebetween, such as without limitation from about 2 hours to about 45 hours, or from about 4 hours to about 40 hours, or from about 6 hours to about 36 hours, or from about 10 hours to about 40 hours, or from about 10 hours to about 36 hours, or from about 10 hours to about 30 hours, or from about 12 hours to about 40 hours, or from about 12 hours to about 36 hours, or from about 12 hours to about 30 hours, or from about 12 hours to about 24 hours, or from about 18 hours to about 40 hours, or from about 18 hours to about 36 hours, or from about 18 hours to about 24 hours.
  • the constant temperature may be in a range of from about -50 °C to about 25 °C, for example without limitation, from about -50 °C to about -15 °C, or from about from about -50 °C to about -10 °C, or from about from about -35 °C to about -10 °C, or from about from about -25 °C to about -10 °C, or from about from about -20 °C to about -10 °C, or from about from about -20 °C to about 0 °C, or from about from about -15 °C to about 25 °C, or from about from about -10 °C to about 25 °C, or from about from about -10 °C to about 20 °C, or from about from about -10 °C to about 10 °C, or from about from about -10 °C to about 20 °C,
  • the varied temperatures may be within a single range of from about -50 °C to about 25 °C, for example without limitation, from about - 50 °C to about -15 °C, or from about from about -15 °C to about 25 °C, or from about from about 0 °C to about 25 °C.
  • the resulting preserved tissue form which comprises a processed tissue sample, with or without additional components, has a water content of less than about 10 wt%, or less than about 8 wt%, or less than about 7 wt%, or less than about 6 wt%, or less than about 5 wt%, or less than about 4 wt%, or less than about 3 wt%, or less than about 2 wt%, or less than about 1 wt%, based on the total weight of the preserved tissue form.
  • the drying phase of the lyopreserving step (H) is performed under vacuum in two steps which include a primary drying step at one or more temperatures within a first range which removes the majority of the ice and frozen solvent (e.g., at least about 70 wt%, or at least about 80 wt%, or at least about 90 wt%), followed by (2) a secondary drying step at one or more temperatures within a second range which removes additional ice and frozen solvent from the frozen tissue sample to produce a preserved tissue form, which comprises a processed tissue sample, with or without additional components, having less than about 10 wt%, or less than about 8 wt%, or less than about 7 wt%, or less than about 6 wt%, or less than about 5 wt%, or less than about 4 wt%, or less than about 3 wt%, or less than about 2 wt%, or less than about 1 wt% water.
  • a primary drying step at one or more temperatures within a first range which removes the majority of the
  • the first and second ranges for drying temperatures may overlap or not.
  • the first range of drying temperatures is from about -100 °C to about 15 °C, or any range therebetween, such as without limitation from about -80 °C to about 0 °C, or from about from about -60 °C to about 0 °C, or from about from about -50 °C to about 0 °C, or from about from about -50 °C to about -15 °C, or from about from about -50 °C to about -10 °C, or from about -45 °C to about 0 °C, or from about -45 °C to about -5 °C, or from about -45 °C to about -15 °C, or from about -60 °C to about 15 °C, or from about -45 °C to about 5 °C, or from about from about -30 °C to about 15 °C, or from about from about -20 °C to about 15 °C, or from
  • the time for which a primary drying step is performed may be, for example without limitation, up to about 40 hours, or from about 1 hour to about 40 hours, or any range there between, such as without limitation, or from about 2 hours to about 36 hours, or from about 6 hours to about 36 hours, or from about 12 hours to about 30 hours, or from about 12 hours to about 24 hours.
  • the secondary drying step is performed at one or more temperatures higher than drying temperatures employed during the primary drying step. In some embodiments, the secondary drying step is performed at one or more temperatures up to about 45 °C, such as up to about 40 °C, or up to about 35 °C.
  • the second range of drying temperatures is from about -25 °C to about 45 °C, or any range therebetween, such as without limitation from about -25 °C to about 45 °C, or from about -20 °C to about 40 °C, or from about -25 °C to about 35 °C, or from about -15 °C to about 45 °C, or from about -15 °C to about 35 °C, or from about -15 °C to about 25 °C, or from about -10 °C to about 45 °C, or from about -10 °C to about 35 °C, or from about -10 °C to about 25 °C, or from about -5 °C to about 35 °C, or from about -5 °C to about 25 °C, or from about 0 °C to about 35 °C, or from about 0 °C to about 25 °C.
  • the time for which a secondary drying step is performed may be, for example without limitation, up to about 40 hours, or from about 1 hour to about 40 hours, or any range therebetween, such as without limitation from about 2 hours to about 36 hours, or from about 6 hours to about 36 hours, or from about 6 hours to about 30 hours, or from about 6 hours to about 20 hours, or from about 6 hours to about 16 hours.
  • the first range of drying temperatures is from about -50 °C to about -15 °C
  • the second range of drying temperatures may be from about -15 °C to about 25 °C, such as from about -10 °C to about 25 °C.
  • the second range of drying temperatures may be from about -15 °C to about 25 °C, such as from about -10 °C to about 25 °C.
  • the retained population of viable cells is a substantial portion of the TO population of viable cells that was present in the tissue sample immediately after lyopreserving (H) and prior to storage at room or ambient temperatures for a period of time (e.g., from at least 14 days to 365 days, , or at least 1 year, 2 years, 3 years, 5 years, or even more, and including any time between 14 days and 5 years).
  • the retained population of viable cells in the preserved tissue form is measurably viable after rehydration of the tissue form.
  • at least a portion of the retained population of viable cells in the preserved tissue form are dormant and become measurably viable after reconstitution with a biologically compatible fluid.
  • the retained population of viable cells is more than 50% of the TO population of viable cells, such as more than 60%, or more than 70%, preferably more than 80% or 85%, and most preferably more than 90%, or 95%, or even 98% of the TO population of viable cells.
  • the tissue-protectant mixture Prior to lyopreserving (H), the tissue-protectant mixture may, optionally, be subjected to a storing step (F) in which the tissue-protectant mixture is held at a storage temperature for a period of storage time.
  • the storage temperature may be a freezing temperature, such as at or below about 0 °C, or below about -50 °C, or even below about -80 °C.
  • a suitable period of storage time may, without limitation, be from about 60 minutes to about 7 days, or from about 60 minutes to about 14 days, or any period of time therebetween).
  • the tissue-protectant mixture may, optionally, be subjected to an incubating step (G) in which the tissue-protectant mixture is held at an incubation temperature such as an ambient or room temperature (i.e., from about 19 °C to about 25 °C, or from about 20 °C to about 23 °C), or a refrigerating temperature (i.e., from above 0 °C to about 18 °C, or from about 1 °C to about 15 °C, or from about 2 °C to about 10 °C, or from about 2 °C to about 8 °C, or from about 2 °C to about 6 °C), or a warming temperature (i.e., from about 26 °C to about 40 °C, or from about 26 °C to about 35 °C, or from about 26 °C to about 30 °C, or from about 28 °C to about 40 °C).
  • an ambient or room temperature i.e., from about 19 °C to about 25 °
  • the incubating step (G) may, for example without limitation, be advantageously performed during or after the step of (E) contacting the processed tissue sample with one or more protectants and before any optional step of (F) storing the tissue-protectant mixture, for a period of storage time, at a storage temperature.
  • performing the incubating step (G) wherein the tissue-protectant mixture is stored at lower temperature e.g., from about 2 °C to about 8 °C, or from about 2 °C to about 6 °C
  • a suitable period of incubation time may, without limitation, be from greater than zero seconds to about 48 hours, such as at least about 20 minutes, or at least about 60 minutes, or at least about 120 minutes, or at least about 180 seconds, or at least 240 minutes, or at least 6 hours, or at least 10 hours, or any value between zero and about 48 hours.
  • the period of incubating time may, without limitation, be at least about 20 minutes, or at least about 30 minutes, or at least about 60 minutes, or at least about 120 minutes, or at least about 180 minutes, or at least 240 minutes, or any value between zero and about 6 hours.
  • any one or more of the contacting step (E), storing step (F), and incubating step (G) may be performed under vacuum, either constant, variable or pulsing, or at pressures greater than atmospheric or ambient pressures.
  • varying the pressures at which these steps are performed may also accelerate or otherwise assisting with the uptake of protectants (e.g., non-permeating protectants) by the tissue sample or cells therein, and/or may enhance or increase viability of the tissue or cells therein.
  • either of the storing (F) and incubating (G) steps may include contacting the tissue sample, or the tissue-protectant mixture, with one or more storage media, basal media, preservatives, or priming media which includes, without limitation, one or more of: amino acids, glucose, salts, vitamins, or other nutrients that promote for cell survival, and cell -preservative components.
  • the tissue sample may be staged in such storage media, basal media, preservatives, or priming media to increase cell viability.
  • cell viability may be enhanced through the inclusion of use known apoptosis inhibitors, including without limitation, dexamethasone, 3-aminobenzamide, aurintricarboxylic acid, sodium orthovanadate, and combinations thereof.
  • apoptosis inhibitors including without limitation, dexamethasone, 3-aminobenzamide, aurintricarboxylic acid, sodium orthovanadate, and combinations thereof.
  • Such staging, storing or incubating may occur during one or more physical and chemical processes performed to accomplish the step (D) of modifying size, shape or other physical characteristics of the tissue sample.
  • Use of cooled storage or staging media may be advantageous if applied to the tissue sample after cutting, slicing and similar techniques to decrease the temperature on the cut surface of the tissue sample.
  • the preserved tissue forms may further include or be combined with one or more additional components, either prior to, during or after the lyopreserving step (H).
  • additional components include, without limitation: mineralized or demineralized bone matrix (cortical or cancellous) in the form of chips, particles, fibers, powder, sheets, chunks, pieces, geometric shapes, etc.; decellularized tissue matrix in the form of chips, particles, fibers, powder, sheets, chunks, pieces, geometric shapes, etc.; other processed or unprocessed tissue forms (whether viable or not) (e.g., cartilage allograft matrix (CAM), lyophilized decellularized delipidized adipose-derived matrix, cryopreserved matrices, etc.); a preservative; a biologically compatible fluid; exogenous cells, viruses, growth factors, proteins, or other biologically active substances; a preservative; an antioxidant; a pharmaceutically active compound; nutritional substances or media; rheology modifiers; crosslinking agents; pH modifiers (buffers
  • the preserved tissue form further includes one or more natural or synthetic polymers which may be biodegradable and present in proportions selected to provide preserved tissue grafts having various preferred rates of degradation and resorption of the graft or portions thereof.
  • Suitable synthetic polymers include, but are not limited to, bioabsorbable polymers such as polylactic acid (PLA), polyglycolic acid (PGA), polylactic-coglycolide acid (PLGA), and other polyhydroxyacids, polycaprolactones, polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, degradable polycyanoacrylates and degradable polyurethanes, as well as a polylactide-coglycolide (PLAGA) polymer or a polyethylene glycol -PLAGA copolymer.
  • PLA polylactic acid
  • PGA polyglycolic acid
  • PLGA polylactic-coglycolide acid
  • PLA polyhydroxyacids
  • natural polymers include, but are not limited to, proteins such as albumin, collagen, fibrin, hyaluronic acid and its derivatives, naturally occurring polyamino acids, and polysaccharides such as alginate, heparin, and other naturally occurring biodegradable polymers of sugar units.
  • the polymeric blend may also include without limitation polycarbonates, polyfumarates, and caprolactones.
  • the method for producing a preserved tissue form may further comprise an optional step of sterilizing the processed tissue sample or the tissue form comprising the processed tissue sample, either before, during or after the lyopreserving step (H).
  • the sterilizing step may be performed using one or more techniques including, without limitation: contacting with chemical sterilants, such as without limitation ethylene oxide, highly acidic solutions, highly basic solutions, and the like; and exposure to gamma irradiation, electron beam (E-beam) irradiation, microwave energy, and the like; and filtering with a filter, such as a 0.2 um filter; as will be familiar to persons of ordinary skill.
  • the sterilizing step may be performed by adding one or more sterilizing agents to the processed tissue sample and/or the preserved tissue form.
  • sterilizing is performed by terminal sterilization (i.e., performed after the lyopreserving step (H) and after the tissue form has been placed and sealed in a package).
  • the protectant could also contain a free radical scavenger or other radio-protectant thus limiting or preventing cell death.
  • the resulting preserved tissue form may be packaged in sterile packaging which may include multiple layers or components.
  • Primary packaging for the tissue may consist of just a single container (jar, vial, bottle, pouch, syringe, cannula, tube, etc.) for both storage media and preserved tissue form, or multiple components such as one container for storage media and preserved tissue form having viable cells, and at least one other container for any non-viable tissue components, and other optional additional components.
  • Packaging components or layers intended to contain the preserved tissue form, with or without storage or other media should include a moisture barrier for preventing or minimizing moisture (water or other fluid) from entering or escaping from the packaging after sealing with the preserved tissue form therein.
  • a processed tissue sample may be placed in a first packaging component and subjected to the lyopreserving step (H) while in the first packaging component which is configured and/or made of material which is sufficiently permeable to allow moisture to escape during the lyopreserving step (H).
  • the first packaging component and preserved tissue sample therein may be placed into a second packaging component, which may be configured and/or made of material which includes a moisture barrier for preventing or minimizing moisture (water or other fluid) from entering or escaping from the packaging after sealing with the preserved tissue form therein.
  • the components of the preserved tissue form may be contacted with one or more preservatives (in solution or not) in packaging and then (H) lyopreserved while packaged.
  • Packaging suitable for use during lyophilization is designed, configured and/or made of materials so as to be compatible with the types of tissue, cells, protectants and other components present in the tissue sample or tissue form to be preserved.
  • packaging suitable for containing preserved tissue samples or preserved tissue forms containing same should be capable of preventing cross-contamination between tissue samples derived from different donors and also provide a sterile barrier if needed during lyopreserving (H).
  • Suitable packaging may also include components which facilitate rehydration, handling of the tissue form (such as picking up with forceps, laying flat, etc.), ., or other preparation of the tissue form such as cutting, perforating, addition of other ingredients such as antibiotics, etc.
  • Lyopreserving (H) the tissue sample may facilitate molding or otherwise forming the tissue sample into an intentional predetermined shape which may, for example, facilitate end use or delivery to a surgical site or wound site of a subject, as well as providing other physical characteristics such as porosity which may enhance and/or accelerate rehydration.
  • Clinical applications of the preserved tissue forms described and contemplated herein include use as a surgical graft for the treatment, repair or regeneration of tissue.
  • the preserved tissue forms are derived from tissue samples comprising bone, they will be useful for repair or treatment of bone defects.
  • the preserved tissue forms comprising bone are also suitable for use in orthopedic surgery to promote bone fusion where needed such as, for example without limitation, intervertebral spinal fusion, posterolateral spinal fusion, long bone fusion, or anywhere bone fusion or bony defect filling is required.
  • the preserved tissue forms provide an advantage over previously known cryopreserved cell-containing bone grafts which maintain long-term cell viability (up to five years), but also require storage at temperatures which are at or well below freezing, e.g., -80 °C, until use. Accordingly, such cryopreserved bone grafts must be thawed prior to implantation and can also present some logistical issues for surgical centers that do not have the appropriate freezer equipment.
  • the preserved tissue forms are derived from tissue samples comprising cartilage
  • they will be useful, for example without limitation, to promote repair and/or regeneration of damaged or worn cartilage where needed such as, for example without limitation, in filling of chondral defects, in filling of osteochondral defects, or in conjunction with other cartilage repair technologies such as, without limitation, microfracture, osteoarticular transfer system (OATS) surgery, and autologous chondrocyte implantation (ACI).
  • Preserved tissue forms derived from tissue samples comprising cartilage would be useful, for example without limitation, in the treatment of joints such as knees, hips, shoulders, elbows, wrists, ankles, knuckles, etc.
  • tissue samples comprising one or more placental tissues (e.g., amnion, chorion, umbilical cord, amniochorion, Wharton’s Jelly, etc.), they will be useful, for example without limitation, for use as a wound or tissue covering to treat / repair ulcers, bums, or other wounds; or to treat / repair interior wounds such as tunneling wounds or surgical wounds.
  • placental tissues e.g., amnion, chorion, umbilical cord, amniochorion, Wharton’s Jelly, etc.
  • Exemplary methods for using a preserved tissue form prepared as described above, for repairing or reconstructing tissue in a subject generally comprise: - providing a preserved tissue form comprising one or more processed tissue samples which have been lyopreserved in the presence of one or more protectants and stored at temperatures above freezing;
  • rehydrating the preserved tissue form by combining (e.g., by mixing, attiring, etc.) the preserved tissue form with a biologically compatible fluid such as, without limitation, saline, blood, bone marrow aspirate (BMA), platelet rich plasma (PRP), and the like, to produce a rehydrated tissue form; and
  • a biologically compatible fluid such as, without limitation, saline, blood, bone marrow aspirate (BMA), platelet rich plasma (PRP), and the like
  • preserved tissue forms which contain a population of viable cells, to be stored at room-temperature or refrigeration temperatures provides increased efficiencies for both end users and tissue processors.
  • Such preserved tissue forms provide improved ease-of-use for the user by removing the need to thaw and also offers added convenience to those users who are likely to otherwise have to use the graft shortly after receipt and/or lack the appropriate storage facilities for frozen tissue.
  • non-frozen storage eliminates the need for costly storage resources (dry ice, liquid nitrogen, tanks and freezers, etc.) and removes certain limitations on tissue shipment (limit on shipment time and size due to dry ice). Additional potential uses of these preserved tissue forms includes, without limitation, implanting in extremities for fusion of an ankle, a foot, a wrist, a hand, etc.
  • the preserved tissue forms comprise bone tissue, such as cancellous bone, cortical bone or a combination of both.
  • preserved tissue forms are not limited to those which include bone tissue, but rather include preserved tissue forms which comprise other tissue types as listed above (e.g., adipose, cartilage, amnion, chorion, etc.) and contain a population of viable cells which remain viable after storage at temperatures above freezing and rehydration.
  • the preserved tissue form comprises processed bone tissue derived from cancellous bone samples and containing a population of endogenous viable cells.
  • demineralized cortical bone fibers or other allograft materials may be added.
  • the parameters and performance of one or more of the steps of the foregoing method for producing a processed tissue sample and a preserved tissue form comprising same may be modified, selected and optimized depending on the type of tissue sample being processed so as to preserve and retain the beneficial bioactive properties inherent to each tissue type.
  • Descriptions of such specific exemplary embodiments will now be provided in connection with processing bone, cartilage and placental tissue types, with the understanding that these descriptions are not limiting and other variations and modifications to the steps of the method described herein are possible to optimize the processing of other tissue types.
  • processed viable cancellous bone tissue is produced by contacting a bone tissue sample with one or more protectants and then lyopreserving the bone tissue sample and one or more protectants to produce the processed bone tissue which remains viable even after storage at room temperature for extended periods of time.
  • viable cells including osteoblasts, osteoprogenitor cells, and mesenchymal stem cells in the preserved tissue form will remain viable for a period of at least 14 days, or at least 28 days, and preferably greater than 90 days after lyopreserving.
  • An exemplary method for producing such a preserved tissue form comprises the steps of: (A) Recovering or receiving a recovered cancellous bone tissue sample (for example, cancellous bone used in the graft may be recovered from the hemi-pelvis, humeral head, or other cancellous bone sites containing viable bone-forming cells or mesenchymal stem cells);
  • a recovered cancellous bone tissue sample for example, cancellous bone used in the graft may be recovered from the hemi-pelvis, humeral head, or other cancellous bone sites containing viable bone-forming cells or mesenchymal stem cells
  • the preserved bone tissue form produced by the above described method comprises processed cancellous bone tissue sample and may be stored at temperatures above freezing (e.g., refrigerated or room temperature), for at least 14 days, or at least 28 days, or at least 56 days, or at least 70 days, and preferably for at least 90 days, at least 180 days, at least 365 days, at least 1 year, 2 years, 3 years, or even longer, and still contain viable endogenous cells.
  • temperatures above freezing e.g., refrigerated or room temperature
  • the preserved bone tissue form comprising processed cancellous bone tissue may be stored at room temperatures (i.e., from about 19 °C to about 25 °C), or refrigeration temperatures (i.e., from greater than 0 °C to about 10 °C), or intermediate temperatures (i.e., from greater than 10 °C to less than about 19 °C).
  • room temperatures i.e., from about 19 °C to about 25 °C
  • refrigeration temperatures i.e., from greater than 0 °C to about 10 °C
  • intermediate temperatures i.e., from greater than 10 °C to less than about 19 °C.
  • All tissue processing steps are performed aseptically. At least one or more of the processing steps are designed to remove immunoreactive elements from the tissue sample, which is demonstrated to not elicit an immune response using an MLR assay, by methods known and understood by persons of ordinary skill in the relevant art. All selected preservation and protectant agents are biologically compatible.
  • an additional component is prepared and added to the bone tissue sample prior to the steps of (E) contacting with one or more protectants and (H) lyopreserving, to produce a preserved tissue form comprising processed cancellous bone tissue and processed cortical bone tissue, as follows.
  • the steps of (A) recovering / receiving, (B) cleaning and (D) modifying the size and shape of a cancellous bone tissue sample to form cancellous bone tissue granules, as described above, are performed.
  • the following additional steps are performed: (AA) recovering or receiving recovered a cortical bone tissue sample;
  • BB cortical bone tissue sample
  • (XI) combining, by mixing, stirring, etc., the cancellous bone tissue granules and demineralized cortical bone fibers in a desired ratio (for example without limitation, 70 wt% cancellous bone tissue granules and 30 wt% demineralized cortical bone fibers , or 60 wt% cancellous bone tissue granules and 40 wt% demineralized cortical bone fibers, or 50 wt% cancellous bone tissue granules and 50 wt% demineralized cortical bone fibers, or 40 wt% cancellous bone tissue granules and 60 wt% demineralized cortical bone fibers or 30 wt% cancellous bone tissue granules and 70 wt% demineralized cortical bone fibers based on the total weight of the bone granules and bone fibers) to produce a bone tissue mixture.
  • a desired ratio for example without limitation, 70 wt%
  • cortical bone samples are recovered from a donor’s femur, tibia, humerus, radius, ulna, and fibula, or other suitable long bones.
  • the long bones are first stripped of soft tissue and the shaft cores are cleared of any cancellous bone.
  • the cortical shafts are cleaned using detergents/surfactants to remove residual blood and lipids, then cut into cross-sectional segments of the appropriate length for milling. Milling of the shaft cross-sections results in elongated fibers of cortical bone. Following demineralization in dilute acid, calcium content of the bone fibers is reduced and the cortical bone fibers become putty-like in handling.
  • this exemplary embodiment further comprises the following steps: (E) Contacting / adding the bone tissue mixture to a protectant solution which contains one or more protectants dissolved in PBS or other biocompatible fluid to form a bone tissue-protectant mixture;
  • the preserved bone tissue form produced by the foregoing method may be described as follows:
  • Lyoprotectant solution Tissue grafts are stored in a sealed, sterile container at a temperature above freezing (e.g., refrigerated or room temp).
  • the preserved tissue form comprises processed cartilage tissue derived from cartilage samples and containing a population of endogenous viable cells.
  • the type of cartilage tissue suitable for use in the presently described preserved tissue forms and methods for making and using them is not particularly limited.
  • the cartilage tissue may be any type, including without limitation, articular cartilage (such as recovered from condyles, etc.), costal cartilage (such as recovered from anterior ends of one or more ribs), fibrocartilage (such as recovered from intervertebral disks), elastic cartilage (such as recovered from ears), other types of cartilage, and combinations thereof.
  • the cartilage tissue for example, may be obtained from osteochondral grafts recovered from one or more donors.
  • Osteochondral grafts typically include a bone portion and a cartilage portion which may, but does not have to, be a condyle or hemicondyle.
  • Suitable osteochondral grafts from which cartilage may be recovered include, without limitation, femurs (distal and proximal), talus, and patella. Although smaller, the patella tends to provide more cartilage than femurs because the layer of cartilage on the patella tends to be much thicker.
  • the cartilage samples, processed cartilage tissue, and preserved cartilage tissue forms comprising processed cartilage tissue may have any size and shape suitable for the intended use and placement of the resulting preserved tissue form comprising the processed cartilage tissue, including, without limitation, particles, strips, chunks, pieces, blocks, sheets, slivers, ribbons, branched and unbranched elongated elements, filaments, fibers, three dimensional geometric shapes such as symmetric and asymmetric spheres, regular and irregular polyhedrons, cones, pyramids, other three dimensional forms having one or more planar or curved surfaces, and irregular three dimensional forms.
  • the preserved tissue form may further comprise cartilage allograft matrix (CAM) such as non-viable freezer-milled cartilage particles, or other materials.
  • CAM cartilage allograft matrix
  • such a preserved tissue form comprising processed cartilage may further comprise, as an additional component, a population of cells selected from: autogenic viable cells isolated from a recipient’s (patient’s) own tissue, non-immunogenic allogenic viable cells (e.g., cells isolated from suitable allogenic sources such as allogenic cartilage), isolated viable cells which have been differentiated for cartilage, bone, etc. (e.g., added to tissue form prior to lyopreserving (H)), “dry cells” (which have been lyophilized, either in contact with a protectant or not, separately from the processed tissue and preserved tissue form).
  • autogenic viable cells isolated from a recipient’s (patient’s) own tissue non-immunogenic allogenic viable cells (e.g., cells isolated from suitable allogenic sources such as allogenic cartilage), isolated viable cells which have been differentiated for cartilage, bone, etc. (e.g., added to tissue form prior to lyopreserving (H)), “dry cells” (which have been lyophilized, either in contact with a protectant
  • a processed viable cartilage tissue is produced by contacting a cartilage tissue sample with one or more protectants and then lyopreserving the cartilage tissue sample and one or more protectants to produce a processed cartilage tissue which remains viable even after storage at room temperature for extended periods of time.
  • viable cells including chondrocytes, chondroblasts, cartilage progenitor cells, and mesenchymal stem cells in the preserved tissue form will remain viable for a period of at least 14 days, or at least 28 days, and preferably greater than 90 days after lyopreserving.
  • An exemplary method for producing such a preserved tissue form comprises the steps of:
  • Recovering or receiving a recovered a cartilage tissue sample may begin with recovering or receiving a recovered bone tissue sample which typically includes a bone portion and a cartilage portion, where the cartilage portion further contains one or more endogenous viable cells including chondrocytes, cartilage-forming cells, and mesenchymal stem cells (for example, a femur having at least one intact condyle with a cartilage surface which contains viable cells); (B 1) Cleaning the bone tissue sample by debriding the bone tissue sample to remove soft tissue;
  • (C) Disinfecting the pieces by contacting them with one or more antibiotics (e.g., place them in a container with a mixture of penicillin, streptomycin, amphotericin B);
  • one or more antibiotics e.g., place them in a container with a mixture of penicillin, streptomycin, amphotericin B
  • an ambient storage media containing one or more antibiotics may be used for concurrently storing and disinfecting the pieces, where such an ambient storage media may contain: a. DMEM, b. Antibiotic-Antimycotic (penicillin / streptomycin / amphotericin B), c. Non-Essential Amino Acid (NEAA) cell culture supplement, d. L-glutamine, e. insulin-transferrin-selenium (ITS) f. L-ascorbic acid (Vitamin C), and g. dexamethasone;
  • cartilage tissue samples are (A) recovered or received “en block,” or as one or more whole tissue sections, and not in an ambient storage media or other stabilizing media
  • the cartilage tissue samples may be subjected to a disinfecting (C) step (for example, by rinsing with PBS, mild surfactant, and peracetic acid and water to remove existing bioburden) prior to or during one or more cleaning (B) and modifying (D) steps
  • grater e.g., an OXO® brand steel grater Model #50581
  • grate the cartilage portion of the shaft e.g., until the cartilage has been removed from the bone portion
  • step (B3) Cleaning and wetting the viable cartilage fibers by rinsing them one or more times (e.g., twice) with PBS or similar biocompatible fluid (gentle agitation during the second rinse with fresh PBS ensures all viable cartilage fibers are wetted while minimizing damage), 1. when the above-described ambient storage media is used to collect the viable cartilage fibers, it must be rinsed off the viable cartilage fibers within three hours from when the viable cartilage fibers are initially soaked in the ambient storage media, therefore, so this rinsing step must generally be performed within three hours of when the grating is commenced (step (D2)));
  • an exemplary protectant solution contains about 0.4 M trehalose and 0.4 mM EGCG, dissolved in IX PBS,
  • the protectant solution may, optionally, also contain one or more additional ingredients such as sugar alcohols, antioxidants, and other additives,
  • contacting the viable cartilage fibers with the protectant solution by be accomplished, for example, by combining a 0.75-0.85 gram quantity of cartilage fibers with about 4-6 milliliters (mL) of protectant solution in a 30 mL jar,
  • the preserved tissue form comprising a processed cartilage tissue sample (i.e., the preserved cartilage tissue form) which is produced by the above described method may be stored at temperatures above freezing (e.g., refrigerated or room temperature), for at least 14 days, or at least 28 days, or at least 56 days, or at least 70 days, and preferably for at least 90 days, at least
  • the preserved cartilage tissue form comprising processed cartilage tissue may be stored at room temperatures (i.e., from about 19 °C to about 25 °C), or refrigeration temperatures (i.e., from greater than 0 °C to about 10 °C), or intermediate temperatures (i.e., from greater than 10 °C to less than about 19 °C).
  • room temperatures i.e., from about 19 °C to about 25 °C
  • refrigeration temperatures i.e., from greater than 0 °C to about 10 °C
  • intermediate temperatures i.e., from greater than 10 °C to less than about 19 °C.
  • the cartilage processing method described above produces viable cartilage fibers which contain viable mesenchymal stem cells, viable chondrocytes, growth factors and matrix proteins, all of which are endogenous and were initially present in the original cartilage tissue sample (i.e., bone and cartilage). Additionally, the viable cartilage fibers are cohesive with one another and, after shaping and implantation into a cartilage void or defect (with or without additional components), tend to remain in the cartilage void or defect, even when the cartilage void or defect and surrounding region are rinsed or irrigated with biocompatible fluid, or gently wiped with a finger, sponge or other suitable device.
  • the preserved tissue form comprising processed cartilage tissue may further comprise one or more additional components as described above (e.g., CAM, fibrin glue, etc.).
  • the preserved tissue form comprising processed cartilage tissue may be packaged, such as in a foil pouch, with or without a moisture barrier.
  • the components of the preserved tissue form, including a processed cartilage tissue sample may be contacted with one or more preservatives (in solution or not) in packaging and then (H) lyopreserved while packaged.
  • All tissue processing steps are performed aseptically. At least one or more of the processing steps are designed to remove immunoreactive elements from the tissue sample, which is demonstrated to not elicit an immune response using an MLR assay, by methods known and understood by persons of ordinary skill in the relevant art. All selected preservation and protectant agents are biologically compatible.
  • a preserved cartilage tissue form comprising a processed cartilage tissue as described herein may be implanted into a recipient (patient, human or non-human) with damaged or otherwise inadequate cartilage as a result, for example without limitation, of disease or naturally or surgically created cartilage voids.
  • the preserved cartilage tissue form further comprises CAM and, when rehydrated with a biocompatible fluid, forms a putty and is moldable, manually or otherwise (e.g., using a mold or other container), to facilitate filling any cartilage void in need of repair.
  • processed (viable) cartilage fibers and one or more protectants may be placed in a mold (i.e., a container having a cavity of desired shape and size), and lyophilized together and then packaged in a kit to be used in a syringe, cannula, or other delivery device.
  • a mold i.e., a container having a cavity of desired shape and size
  • one or more additional components such as, without limitation, CAM, may be combined with the processed cartilage fibers in the mold and lyophilized together to form a preserved cartilage tissue form having a predetermined size and shape (i.e., the aforesaid desired size and shape of the cavity).
  • the processed cartilage fibers are lyophilized (in a mold or not), then packaged in a kit, with one or more additional components such as, without limitation, CAM, also packaged in the kit, but separate from the processed cartilage fibers, with the intent that the processed cartilage fibers and additional components are combined with one another and, optionally, a biocompatible fluid, at the time of use and implantation into (or onto) a subject (patient).
  • Such preserved cartilage tissue forms i.e., the processed cartilage fibers
  • the preserved tissue form comprises processed placental tissue derived from placental samples and containing a population of endogenous viable cells.
  • a preserved tissue form comprising processed placental tissue may further comprise, as an additional component, a population of cells selected from: autogenic viable cells isolated from a recipient’s (patient’s) own tissue, non-immunogenic allogenic viable cells (e.g., cells isolated from suitable allogenic sources such as allogenic cartilage), isolated viable cells which have been differentiated, “dry cells” (which have been lyophilized, either in contact with a protectant or not, separately from the processed tissue and preserved tissue form).
  • a processed viable placental tissue comprising processed amnion tissue and processed chorion tissue
  • viable cells including one or more types of viable cells including epithelial cells and stromal cells (such as fibroblasts and mesenchymal stem cells) in the preserved tissue form, will remain viable for a period of at least 14 days, or at least 28 days, and preferably greater than 90 days after lyopreserving.
  • An exemplary method for producing such a preserved tissue form comprises the steps of:
  • A Recovering or receiving a recovered placenta sample which includes at least an amnion membrane and a chorion membrane; a.
  • umbilical cord may also be included.
  • umbilical cord also may be cut free from the placental disk and then cleaned and processed in a similar manner as the subsequent steps.
  • B2 Cleaning and removing blood and blood clots from each of the amnion and chorion membranes by:
  • RBC lysis solution containing ingredients which lyse red blood cells and break up blood clots (e.g., a buffer solution comprising streptokinase [commercially available as MP BIOMEDICALS brand from Thermo Fisher Scientific of Waltham, Massachusetts, U.S.A.], and a red blood cell lysis buffer [commercially available from Sigma Aldrich of St. Louis, Missouri, U.S.A.]),
  • separating the chorion membrane from the RBC lysis solution rinsing the chorion membrane (one or more times) with a biocompatible fluid (e.g., HBSS) and dabbing with wetted wipes and/or sterile cotton applicators to remove additional blood and blood clots,
  • a biocompatible fluid e.g., HBSS
  • a biocompatible buffer solution e.g., HBSS
  • wetted wipes e.g., soak and wipe twice for about 10 to about 20 minutes each time
  • (C) Disinfecting the amnion and chorion membranes (together or separately) by contacting them with one or more antibiotics, preferably with agitation (e.g., place them in a container with a mixture of vancomycin, gentamicin, amphotericin B and agitate for about 30 to about 60 minutes); (B3) Cleaning the amnion and chorion membranes to remove the one or more antibiotics by soaking and rinsing, preferably with agitation (one or more times) with a biocompatible fluid (e.g., perform a first rinse in a flask with HBSS and shaking at 65 rpm for 5-10 min, repeat for a second rinse (preferably with fresh HBSS), and perform a third rinse in a flask with HBSS (preferably fresh) and shaking at 65 rpm for 30-40 min),
  • a biocompatible fluid e.g., perform a first rinse in a flask with HBSS and shaking at 65 rpm for 5-10 min
  • arranging the amnion and chorion membranes together by placing the amnion membrane on a backing material, optionally with the epithelial side facing down and in contact with the backing material, and placing the chorion membrane on top of the amnion membrane, optionally with the trophoblast side (with or without the trophoblast layer present) facing up and not in contact with the amnion membrane, then cutting the layered amnion and chorion membranes into smaller amnion-chorion pieces of desired size and shape (still with backing material), and placing the cut pieces back into the biocompatible fluid (e.g., HBSS) to maintain hydration of the cut pieces during the remaining cutting;
  • the biocompatible fluid e.g., HBSS
  • the cut amnion-chorion pieces may be soaked or stored in a biocompatible fluid (e.g., HBSS) to maintain hydration of the cut pieces during the remaining cutting, and removed from the biocompatible fluid prior to contacting with one or more protectants;
  • a biocompatible fluid e.g., HBSS
  • an exemplary protectant solution contains about 0.5 M trehalose and 4.0 mM EGCG, dissolved in HBSS,
  • the protectant solution may, optionally, also contain one or more additional ingredients such as sugar alcohols, antioxidants, and other additives,
  • the contacting time may be from about 15 to about 60 minutes
  • the contacting temperature may be from greater than 0 °C to about 10 °C, (H) Lyopreserving the amnion-chorion tissue-protectant mixture to produce a preserved amnion-chorion tissue form (comprising both processed amnion and processed chorion), by performing the following process;
  • the frozen amnion-chorion tissue-protectant mixture a. at either a constant temperature, or at a varied temperature in a range of either from -50 °C to less than -10 °C, or from -10 °C to 25 °C, preferably in a range of from -10 °C to 25 °C; b. at a pressure of from 0.013 kPa to 0.13 kPa (i.e., from 100 mTorr to 1000 mTorr); and c. for a period of time of at least 60 minutes, or at least 180 minutes, or at least 200 minutes, or at least 300 minutes, or at least 400 minutes, or at least 600 minutes, or at least 900 minutes.
  • a color indicator such as phenol red
  • phenol red may be added to the biocompatible fluid to impart a visible color to the amnion and chorion membranes to facilitate visualization during cutting.
  • the cut amnion-chorion pieces may be placed into a retainer, netting, mesh, or other type of permeable container after the size modifying step (D) and prior to performing one or more additional processing steps (e.g., contacting with protectants, rinsing, etc.).
  • the step of (E) contacting the cut amnion-chorion tissue pieces with the protectant solution may include draining the protectant solution after the desired period of contacting time, briefly (about 5 minutes) soaking or rinsing the cut amnion-chorion tissue pieces with a biocompatible fluid (e.g., HBSS); draining excess fluid from the cut amnion-chorion pieces and placing them into one or more breathable pouches (such as without limitation, Tyvek pouches) and sealing the pouch(es), and perform the (H) lyopreserving step while the amnion-chorion pieces are sealed in the pouches.
  • a biocompatible fluid e.g., HBSS
  • the pouches containing lyopreserved amnion-chorion tissue may be placed and sealed in an external packaging material, such as moisture-barrier pouches.
  • the preserved tissue form comprising a processed amnion-chorion tissue (i.e., the preserved amnion-chorion tissue form) produced by the above described method may be stored at temperatures above freezing (e.g., refrigerated or room temperature), for at least 14 days, or at least 28 days, or at least 56 days, or at least 70 days, and preferably for at least 90 days, at least 180 days, at least 365 days, at least 1 year, 2 years, 3 years, or even longer, and still contain viable endogenous cells.
  • temperatures above freezing e.g., refrigerated or room temperature
  • the preserved cartilage tissue form comprising processed cartilage tissue may be stored at room temperatures (i.e., from about 19 °C to about 25 °C), or refrigeration temperatures (i.e., from greater than 0 °C to about 10 °C), or intermediate temperatures (i.e., from greater than 10 °C to less than about 19 °C).
  • room temperatures i.e., from about 19 °C to about 25 °C
  • refrigeration temperatures i.e., from greater than 0 °C to about 10 °C
  • intermediate temperatures i.e., from greater than 10 °C to less than about 19 °C.
  • the placenta (e.g., amnion and chorion) processing method described above produces pieces of layered amnion and chorion membranes which contain viable epithelial and stromal cells (such as fibroblasts and mesenchymal stem stems), growth factors and matrix proteins, all of which are endogenous and were initially present in the original placenta tissue sample (i.e., amnion and chorion).
  • viable epithelial and stromal cells such as fibroblasts and mesenchymal stem stems
  • growth factors and matrix proteins all of which are endogenous and were initially present in the original placenta tissue sample (i.e., amnion and chorion).
  • the preserved amnion-chorion tissue form may further comprise one or more additional components as described above (e.g., exogenous cells, other processed tissues or grafts, etc.).
  • the preserved tissue form comprising processed amnion-chorion tissue may be packaged, such as in a pouch, preferably within a moisture barrier package.
  • the components of the preserved tissue form, including a processed cartilage tissue sample may be contacted with one or more preservatives (in solution or not) in packaging and then (H) lyopreserved while packaged. All tissue processing steps are performed aseptically.
  • At least one or more of the processing steps are designed to remove immunoreactive elements from the tissue sample, which is demonstrated to not elicit an immune response using an MLR assay, by methods known and understood by persons of ordinary skill in the relevant art. All selected preservation and protectant agents are biologically compatible.
  • the preserved tissue form comprises processed placental tissue derived from placental samples and containing a population of endogenous viable cells
  • the placental tissue may comprise processed umbilical cord tissue sample.
  • a processed viable placental tissue comprising processed umbilical cord tissue may be produced by a method similar to that described above in connection with the processing of amnion and chorion tissues, except that at least some of the steps of (B) cleaning and (D) modifying the size, shape and other physical characteristics will be different due to the physical and other differences between amnion, chorion and umbilical cord.
  • one or more of several cleaning steps may be performed including, for example without limitation, (Bl) cutting and separated the umbilical cord tissue sample from the remaining placental tissues, (B2) separating and removing blood vessels from the umbilical cord tissue sample, and (B3) rinsing the umbilical cord tissue sample with one or more biocompatible fluids to remove unwanted materials (e.g., blood, debris, etc.).
  • the umbilical cord tissue sample may also be subjected to the step of (D) modifying one or more of the size and shape of the umbilical cord tissue sample by cutting the umbilical cord longitudinally and spreading or flattening the umbilical cord into a planar or sheet like configuration.
  • Such size and shape modification steps (D) may be followed by one or more additional cleaning steps (B) such as rinsing or soaking with one or more biocompatible fluid. It should be noted that the foregoing steps may be performed in a different order than described above, according to the judgment of persons or ordinary skill in the relevant art.
  • the umbilical cord tissue sample is (E) contacted with one or more protectants and then the resulting umbilical cord tissue-protectant mixture will be (H) lyopreserved to produce a processed umbilical cord tissue which remains viable even after storage at room temperature for extended periods of time.
  • viable cells including one or types of viable cells including epithelial cells and stromal cells (such as fibroblasts and mesenchymal stem cells) in the preserved tissue form, will remain viable for a period of at least 14 days, or at least 28 days, and preferably greater than 90 days after lyopreserving.
  • Such a processed umbilical cord tissue form may further comprise other processed tissues such as, without limitation, processed amnion, processed chorion, or both, as well as one or more additional components, etc.
  • a preserved tissue form comprising processed umbilical cord tissue may further comprise, as an additional component, a population of cells selected from: autogenic viable cells isolated from a recipient’s (patient’s) own tissue, non- immunogenic allogenic viable cells (e.g., cells isolated from suitable allogenic sources such as allogenic cartilage), isolated viable cells which have been differentiated, “dry cells” (which have been lyophilized, either in contact with a protectant or not, separately from the processed tissue and preserved tissue form).
  • a tissue sample is set aside at any point during a processing method at which the presence and/or viability of the cells is desired to be measured, so that cell viability/ biological activity of the tissue can be evaluated at that point using commercially available methods.
  • tetrazolium salts e.g., 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 2H-tetrazolium (MTS), 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5- carboxanilide (XTT), and other water soluble tetrazolium salts (e.g., WST-1, -3, -4, -5, -8, -9, -10, and -11)), live-dead assays, ATP assay, CCK-8 assay and dye exclusion assays such as Trypan Blue,
  • a viability assay based on the metabolic activity of a sample is performed by measuring the ATP content in the sample.
  • the assay is performed by thawing frozen tissue samples (if needed) and then transferring the tissue samples into a rinse basin.
  • the thawed and/or rinsed tissue samples are combined with an assay reagent and incubated on an orbital shaker. After incubation, aliquots of the incubated reagent are transferred into a 96-well plate and raw luminescence values (in RLU), for example, are obtained using a plate reader.
  • a standard curve is prepared by creating serial dilutions of known concentrations of an ATP standard, combining with assay reagent, incubating on an orbital shaker, and then reading the RLU of each dilution.
  • the dilutions’ RLUs are plotted against the known concentrations of each serial dilution to generate an equation, which is then used to convert RLU of the tissue samples to concentrations of ATP.
  • the tested tissue samples may be rinsed in water or a biologically compatible fluid (such as, without limitation, 5% Dextrose in Lactated Ringer’s Solution (D5LR), phosphate buffered saline (PBS), saline, HBSS, etc.), before being placed into pre-weighed weighing pans.
  • a biologically compatible fluid such as, without limitation, 5% Dextrose in Lactated Ringer’s Solution (D5LR), phosphate buffered saline (PBS), saline, HBSS, etc.
  • D5LR 5% Dextrose in Lactated Ringer’s Solution
  • PBS phosphate buffered saline
  • HBSS HBSS
  • the tissue sample may then be dried (e.g., if wet) and weighed, and the concentration of ATP per tissue sample is converted to amount of ATP per weight of tissue sample.
  • the tissue sample may be undried, i.e., weighed in a wet condition, or it may
  • tissue sample is wet or dry prior to incubation with assay reagent, and whether a tissue sample is rinsed (and with what type of fluid) prior to drying and weighing, will depend on the type of tissue.
  • bone tissue may be wet prior to incubation with assay reagent and not rinsed or weighed after RLU values are obtained, so that the pre-testing wet weight is used to calculate the amount of ATP per weight of tissue sample.
  • placental (e.g., amnion, chorion, etc.) tissue may be rinsed after obtaining RLU values, then dried and weighed, as explained above.
  • the tissue sample being tested for viable cell population content may be wet or dry and the foregoing ranges for the results of such testing are applicable to both wet and dry tissue samples.
  • a preserved tissue sample has a pre-lyopreservation population of endogenous viable cells and a post-lyopreservation (i.e., Week 0) population of endogenous viable cells.
  • the post-lyopreservation population of endogenous viable cells is a portion (e.g., a percentage) of the pre-lyopreservation population of endogenous viable cells.
  • the post-lyopreservation population of endogenous viable cells is also a portion (e.g., a percentage) of the pre-contact population of endogenous viable cells.
  • the preserved tissue samples contain populations of endogenous viable cells which are substantially comparable in quantity and proportion to populations of endogenous viable cells contained in cryopreserved tissue forms (and cryopreserved tissue forms comprising them), where the preserved and cryopreserved tissue samples are of the same type of tissue and the populations of endogenous viable cells of each of the preserved and cryopreserved bone tissue samples are measured at the same point of processing or after the same period of time of storage after preservation and cryopreservation.
  • a preserved bone tissue sample comprises a population of endogenous viable cells which is substantially comparable, i.e., within ⁇ 15%, or within ⁇ any percent between 15% and 1%, to the population of endogenous viable cells contained in a cryopreserved bone tissue sample, wherein both of the populations of endogenous viable cells are any one of: post-contact (i.e., measured after contacting with one or more protectants and after contacting with one or more cryopreservation agents, or “pre-lyopreservation” and “pre-cryopreservation,” respectively) populations of endogenous viable cells, post-lyopreservation and post-cryopreservation populations of endogenous viable cells, respectively (i.e., TO or Week 0 populations), or retained populations of endogenous viable cells (i.e., measured after a period of storage time).
  • post-contact i.e., measured after contacting with one or more protectants and after contacting with one or more cryopreservation agents, or “pre-lyopre
  • a preserved amnion tissue sample comprises a population of endogenous viable cells which is substantially comparable, i.e., within ⁇ 85%, or within ⁇ any percent between 85% and 1%, to the population of endogenous viable cells contained in a cryopreserved amnion tissue sample, wherein both of the populations of endogenous viable cells are measured at the same point of processing or after the same period of storage time, as explained above.
  • a preserved cartilage tissue sample comprises a population of endogenous viable cells which is substantially comparable, i.e., within ⁇ 50%, or within ⁇ any percent between 50% and 1%, to the population of endogenous viable cells contained in a cryopreserved cartilage tissue sample, wherein both of the populations of endogenous viable cells are measured at the same point of processing or after the same period of storage time, as explained above.
  • tissue samples were human tissues obtained from eligible donors after obtaining written informed consent, and applicable tissue regulations for receipt and disposition of tissues were strictly followed.
  • cancellous tissue samples were recovered from a single donor, and processed to provide cancellous granules. Multiple samples of the processed cancellous granules were preserved after contact with protectants in solution, in accordance with the methods described hereinabove, and analyzed for cell viability by measuring ATP. The ATP results reported below are based on the mathematical average of the measured ATP results for all of the aforesaid samples derived from the single donor of Experiment 1.
  • cancellous tissue samples comprising cancellous bone were recovered from a single donor (different from the donor of Experiment 1) and processed to provide cancellous granules
  • cortical bone tissue samples were recovered from the same single donor of Experiment 2 and processed to provide cortical fibers.
  • Multiple samples, each comprising both cancellous granules and cortical fibers, were preserved after contact with protectants in solution, in accordance with the methods described hereinabove, and analyzed for cell viability by measuring ATP.
  • the ATP results reported below are based on the mathematical average of the measured ATP results for all of the aforesaid samples comprising both cancellous granules and cortical fibers and derived from the single donor of Experiment 2.
  • the solution was sterile filtered using a 0.2pm membrane filter.
  • Viable cancellous tissue (granules) and demineralized cortical tissue (fibers) were obtained by sterile processing techniques as described hereinabove in connection with processing viable cancellous bone tissue (i.e., for cancellous granules: (A) recovered/received cancellous bone sample, (B) cleaned by debriding and rinsing, (D) modified by (1) cutting and then (3) milling to produce granules of average particle size from 425 pm to 4 mm), followed by (C) disinfected to remove bioburden by rinsing with peracetic acid, mild surfactant, and buffered saline; and for cortical fibers: (AA) recovered/received cortical bone sample, (BB) modified by (1) cutting, (2) milling to produce fibers of average width from 80 um to 150 um and average length from 8 mm to 12 mm), and then (3) demineralizing the fibers to a mineral content of less than 8 wt%).
  • a first set of samples of about 0.5g of the cancellous tissue granules from Experiment 1 were measured and separated, and each of the first and second post-contact samples was tested per the ATP viability assay procedures described above, which provided “Pre-Lyo” (i.e., “post-contact and incubation”) ATP values.
  • lyopreservation solution recipe i. To the desired volume of HYCLONE® media, added EGCG at a concentration of 0.945mg/mL and added trehalose at a concentration of 37.83mg/mL to form lyopreservation solution.
  • Table 5B below and Figure 1 show the % Retained ATP at 4, 8, 10 and 12 weeks as compared to viability at Week 0, which is calculated as follows:
  • Example 3 Preserved Tissue Form Containing Both Viable Cancellous Bone Granules and Demineralized Cortical Bone Fibers with Demonstrated Viability After Lyopreservation and Storage at Room Temperature (up to 12 Weeks).
  • cancellous and cortical bone tissue samples from 3 different donors were obtained, processed and combined, as follows, to produce a total of 18 combined test samples.
  • cancellous tissue samples comprising cancellous bone were recovered and processed to provide cancellous granules
  • cortical bone tissue samples were recovered and processed to provide cortical fibers.
  • Quantities of cancellous granules and cortical fibers derived from the same donor were measured and combined to produce three combined test samples per donor, each of which contained about 40 wt% cancellous granules and about 60 wt% cortical fibers, the wt % being based on the total weight of the combined cancellous granules and cortical fibers of each sample.
  • the total weights of the test samples ranged from 1.3g to 1.6g.
  • the test samples were preserved after contact with protectants in solution, in accordance with the methods described hereinabove, and analyzed for cell viability by measuring ATP.
  • the ATP results reported below are based on the mathematical average of the measured ATP results for each of the three test samples comprising both cancellous granules and cortical fibers and derived from a common donor.
  • Protectant solution was prepared by dissolving trehalose and EGCG into PBS IX at concentrations of 0.4M and 4mM, respectively.
  • Viable cancellous tissue (granules) and demineralized cortical tissue (fibers) were obtained by sterile processing techniques as described in Example 1 above, Part B.l.
  • each sample included 0.5g cancellous granules and 0.8g cortical fibers.
  • Tissue was lyopreserved generally according to the recipe provided below in Table 6. Table 6
  • test samples containing about 1.3-1.6g of total tissue Prior to contact with protectant solution (i.e., prior to step B.6. above), one or more test samples containing about 1.3-1.6g of total tissue were measured and tested per the ATP viability assay procedures described above, which provided “Baseline” ATP values. 11. Prior to lyopreservation but post-contact and incubation with the protectant solution (i.e., prior to step B8 above), one or more test samples containing about 1.3-1.6g of total tissue were measured and tested per the ATP viability assay procedures described above, which provided “Pre-Lyo” (i.e., “post-contact and incubation”) ATP values.
  • Pre-Lyo i.e., “post-contact and incubation”
  • samples were rehydrated by adding IX PBS to each jar to the fill line and letting sit at room temperature for 5 minutes.
  • Baseline samples viable cancellous granules and demineralized bone fibers tested immediately prior to use in experiment, with no exposure to lyophilization solution, therefore, indicative of “pre-contact” population of viable cells
  • Table 7B shows the % Retained ATP 12 weeks as compared to viability at Week 0, which is calculated for each donor using the average ATP values for the 3 test sample replicates, as follows:
  • % Retained ATP (Average Week 12 ATP Value / Average Week 0 ATP Value ) x 100
  • Week 0 ATP Value [Week 0 ATP Sample 1 + Week 0 ATP Sample 2 + Week
  • Average Week 12 ATP Value [Week 0 ATP Sample 1 + Week 0 ATP Sample 2 +
  • Distal Femur osteochondral (OC) grafts (tissue samples) were received and/or packaged in ambient storage media a. Composition of the ambient storage media was as follows: i. 0.95XDMEM, ii. supplemented with 0.125uM Dexamethasone, and iii. 0.95X Antibiotic-Antimycotic (Penicillin/Streptomycin/ Amphotericin B). OC grafts in ambient storage media and necessary supplies and equipment were passed into a sterile hood (biological safety cabinet). a. All following steps are performed aseptically One Nalgene container was filled with one full bag (250mL) of ambient storage media.
  • OC Graft was removed from its packaging and the leftover solution drained off, down the drain.
  • the OC Graft was placed in ACT Vise by clamping the bone portion of the graft into the vise by turning the handle until secure. Care was taken not to clamp or damage areas of cartilage.
  • Grating cartilage to produce viable cartilage fibers was performed by pressing firmly on the cartilage portion of tissue with an OXO® grater (Model #50581), using a stroking motion directed toward yourself. Using two hands facilitates the grating process. After four strokes, the grater was dipped in the Nalgene container with ambient storage media. a. Care was taken not to grate any areas of damaged cartilage or bone tissue b.
  • the OC graft was repositioned in the ACT Vise as necessary to accomplish grating and formation of cartilage fibers
  • the time that the first portion of fibers are placed in the ambient storage media was recorded. a. Viable cartilage fibers must be collected in ambient storage media and drained within 3 hours of when the first set of fibers were soaked. Step 5 was repeated until all cartilage was grated into fibers. 9. Once all cartilage was grated, the mesh basket designated was placed, with the lid off, over a sieve. The grated fibers and ambient storage media were poured into the basket. Once the storage media drained, the lid of the mesh basket was closed and secured. The basket was lifted up and down to drain residual storage media. 10. 1 liter of PBS was poured over the cartilage fibers in the basket to rinse off any excess media not removed during draining.
  • a Nalgene container was filled with PBS and the mesh basket placed into the container, ensuring that the fibers were submerged completely.
  • the viable cartilage fibers were stirred and fluffed to release any surface tension from the PBS with the bottom of the mesh basket. This step is helpful to ensure that all the fibers are evenly wetted throughout the basket.
  • cryopreservation solution samples For cryopreservation solution samples, the time the first jar was filled was recorded. All samples must be placed in the cryopreservation apparatus (Thermo Scientific CryoMed Model 7454, the “CryoMed”) and the CryoMed must be started within 2 hours from when the first sample j ar was filled. For lyoprotectant solution samples, the time the first jar was filled was recorded. All samples were incubated for at least one hour from when the first sample jar was filled (at ambient temperature, 19-23°C). a.
  • Each sample-containing jar to be cryopreserved was placed into a foil pouch horizontally and the pouches sealed.
  • the CryoMed was turned on and the desired cryopreservation recipe/procedure was selected, which is provided in Table 8 below:
  • cryopreservation solution was decanted from the jar and PBS added to the jar to the fill line to rinse cryopreservation solution from the fibers.
  • PBS was decanted from the jar to provide relatively dry fibers for cell viability testing with CellTiter Glo Reagent.
  • cryopreserved samples were tested for cell viability as described above (in Characterization Test Methods section) with CellTiter-Glo Reagent.
  • Each sample-containing jar to be lyopreserved was placed onto an aluminum or stainless steel dish and inserted into the lyophilizer (apparatus as described in Example 1 above).
  • the lyopreserved viable cartilage fibers were rehydrated with PBS IX by filling each loz jar to the fill line.
  • the lyopreserved samples were tested for cell viability as described above (in Characterization Test Methods section), and specifically as described below, using CellTiter-Glo reagent.
  • the CellTiter-Glo reagent was thawed in a water bath at room temperature. At least 20 minutes was allowed for a full lOOmL set to thaw. 2. Once thawed, the bottle was inverted multiple times and rolled to homogenize the reagent. Reagent was stored away from light until use.
  • DMEM was aliquoted into a 50mL tube and allowed to reach room temperature.
  • a blank was created by mixing lOOOuL DMEM and lOOOuL CellTiter-Glo into a 15mL that does not contain any cartilage fibers.
  • tissue-protectant mixtures Added 4mL of lyopreservation solution to each jar containing weighed samples of milled cancellous bone tissue designated for lyophilization to form tissue-protectant mixtures.
  • cryopreservation samples were prepared whereby 0.5g of milled cancellous tissue were tested for baseline cell viability. 3.
  • cryopreservation solution was added to the fill line on the inside of the jar. The lid was tightly screwed shut.
  • cryopreservation samples were decanted of cryoprotectant solution, rinsed with PBS filling the jar up to the fill-in, and once again decanted.
  • % of Baseline ATP (Average Week 0 ATP value / Average Baseline ATP value) x 100
  • Lyoprotectant Solution was prepared as described in Example 1 above but having the following content: 0.5M trehalose, 4mM Epigallocatechin gallate (EGCG), in HBSS
  • the lyoprotectant solution was protected from light and refrigerated until time of use.
  • the amnion membrane was peeled apart from the chorion membrane by hand and then cut free from the umbilical cord with scissors.
  • the flask was placed onto an orbital shaker and agitated at 150RPM for 90 minutes. 7. Meanwhile, the amnion was manually cleaned, by dabbing and wiping with wetted wipes while soaking in HBSS to remove blood and blood clots, two times for 10-20 minutes each time.
  • the chorion was manually cleaned by dabbing and wiping with wetted wipes and cotton applicators while soaking in the HBSS to remove residual blood and blood clots.
  • Antibiotic solution was prepared by making a solution of 50ug/mL vancomycin, 50ug/mL gentamycin, and 2.5ug/mL amphotericin B in HBSS.
  • the amnion and chorion were transferred into a flask with antibiotic solution and agitated at 65RPM for 60 minutes. 12. The amnion and chorion were transferred into a flask with fresh HBSS and agitated at
  • the amnion and chorion were transferred into a flask with fresh HBSS and agitated at 65RPM for 5 minutes.
  • amnion and chorion were transferred into a flask with fresh HBSS with phenol and agitated at 65RPM for 30 minutes, to impart a reddish color to the tissue for easier visualization during cutting.
  • the chorion was transferred into a basin of fresh HBSS and then manually cleaned by dabbing and wiping with wetted wipes and cotton applicators while soaking in HBSS to remove residual blood and blood clots.
  • the amnion was placed on a backing material with epithelial side facing down, toward the backing.
  • the chorion was placed on top of the amnion, with the trophoblast side facing upward, away from the amnion.
  • the layered amnion/chorion composite was cut using a rolling bladed cutter into samples of approximately 5x5 cm. 20.
  • the amnion/chorion sample still on backing was placed into a snap retainer and then immersed into HBSS until all cutting was completed.
  • tissue containment configurations were tested across donors, such as placing tissue on backing into a netting mesh, placing tissue on netting mesh into a retainer, and placing tissue on backing into a retainer.
  • the retainers containing amnion/chorion tissue were placed into lyoprotectant solution and refrigerated for 30-60 minutes.
  • the sealed pouches were placed with breathable side up into a lyophilizer (apparatus as described in Example 1 above) and lyophilized using a programmed recipe as described in Tables 13-17 provided below. 25. After lyo cycle was completed, pouches were removed and sealed into foil pouches as a moisture barrier pouch.
  • Placenta Tissue Sample was processed as previously described above in Example 6, Part A, until Step 16, when chorion was being cleaned after antibiotic soak.
  • the trophoblast layer of the chorion was removed by gently peeling loose the trophoblast layer using fingers, cotton applicators, instruments such as dissecting forceps, or wetted wipes. 2.1. The removal of the trophoblast layer also resulted in the removal of residual blood and blood clots embedded within the tissue, leaving very little residual blood on the remaining chorion.
  • Table 13 provides a summary of the features and conditions of each of the above- described Bilayer Lyopreserved Tissue Forms, both with and without trophoblast layer, including the lyopreservation recipe performed in the lyophilizer, the packaging configuration and the tissue configuration.
  • the Iteration # corresponds to placental tissue samples recovered from different donors, or to different lyo recipes or packaging configurations within the same donor.
  • a unit of lyopreserved viable amnion/chorion bilayer tissue form (prepared as described above in Example 6, Parts A-B) was cut into approximately 4cm 2 pieces for the ATP assay. Each piece was rehydrated by immersing in PBS for 10 minutes, and the amnion and chorion layers were peeled apart using dissecting forceps to test the layers by ATP assay separately. Each approximately 4cm 2 rehydrated tissue piece was combined with 0.5mL DMEM and 0.5mL assay reagent in a well plate and incubated on an orbital shaker in the dark for 20 minutes at room temperature.
  • AM- and CM- refer to "Amnion” and “Chorion” without trophoblast layer, lyophilized as a bilayer, rehydrated for lOmin in PBS then peeled apart prior to testing ATP separately L AM/CM- could not be separated for testing for Iteration #3
  • Supplemented DMEM/F12 media was prepared by adding 10% FBS, 1% PenStrep solution, and 1% glutaGRO solution final v/v to DMEM/F12 media without phenol red
  • the prepared media was stored at 4°C in the dark. Immediately before use, the prepared media was warmed in a 37°C water bath.
  • each lyopreserved 5cm x 5cm amnion/chorion bilayer sheet sample was removed from the outer foil pouch, inner Tyvek pouch, retainer, and backing, and immersed in a weigh pan of room temperature PBS for approximately 10 minutes. After rehydration, the amnion and chorion membranes were peeled apart and each membrane from each sample was placed into a separate well of a 6 well tissue culture plate, to which 5mL of supplemented DMEM/F12 culture media was added. Each 5cm x 5cm amnion or chorion membrane was allowed to equilibrate in media overnight in a CO2 incubator at 37°C and 5% CO2 level.
  • Enzymatic Tissue Digestion 1. A 0.75% collagenase II solution was prepared by adding lg of powdered collagenase II per 133mL of DMEM/F12 media without phenol red. The collagenase II solution and 0.25% trypsin solution were each warmed in a 37°C water bath immediately prior to their use in the subsequent steps. 2. Each 5cm x 5cm amnion (AMT, AM-) and chorion sample (CM+, CM-) was placed into a separate 50mL conical tube containing 40mL of collagenase II solution.
  • Each conical tube was capped and laid sideways on an incubator shaker at 65rpm for 40 minutes at 37°C, and then centrifuged at 2000rpm for 10 minutes at ambient temperature. Taking care not to aspirate tissue, liquid in each tube was aspirated down to 5mL remaining, and then 40mL of 0.25% trypsin was added. Each conical tube was recapped and laid sideways on an incubator shaker at 65rpm for 15 minutes at 37°C. After shaking, 5mL of Fetal Bovine Serum was added to each tube to neutralize the trypsin.
  • Each tube’s contents was poured through a separate lOOpm cell strainer and into a new 50mL conical tube, to remove remaining tissue and debris.
  • the new conical tubes were centrifuged at 2000rpm for 10 minutes at ambient temperature.
  • the liquid in each tube was aspirated down to 5mL remaining, and then the last 5mL of solution was transferred into a 15mL conical tube.
  • the 15mL conical tubes were centrifuged at 2000rpm for 10 minutes at ambient temperature.
  • the supernatant from each conical tube was aspirated out of each tube and lmL of DMEM/F12 without phenol red was added to each.
  • the contents of each tube was pipetted up and down for a minimum of 10 times to resuspend the cells, until no visible cell pellets were visible.
  • the live/dead stain is light sensitive, all live/dead staining steps were performed in the dark.
  • the reagents from a live/dead viability kit (LIVE/DEAD® Viability/Cytotoxicity Kit, Invitrogen) were thawed at room temperature.
  • 20pL of 2mM ethidium homodimer-1 (EthD-1) was added to lOmL Dulbecco's Phosphate-Buffered Saline (DPBS) to form an EthD-1 solution, which was vortexed to mix.
  • 5pL of 4mM calcein AM was added to the EthD-1 solution and vortexed to mix.
  • the live/dead working solution (4mM EthD-1, 2pL calcein AM) was kept in foil to avoid exposing the solution to light before it was applied to the samples of enzymatically digested cell suspension, as follows.
  • microcentrifuge tube containing enzymatically digested cell suspension was centrifuged in a microcentrifuge for 6 minutes at 300x g. The resulting supernatant was removed by aspirating. lmL of the live/dead working solution was added to each microcentrifuge tube, followed by pipetting up and down to resuspend cells. The microcentrifuge tubes were incubated in the dark for 20 minutes at room temperature.
  • j 8 was used to analyze each representative image produced by the foregoing steps and determine the number of viable cells and nonviable cells.
  • IMAGEJ was obtained from the National Institutes of Health, of Bethesda, Maryland, USA. The software was downloaded from the NIH website at https://imagej.nih.gov/ij/. Using IMAGEJ, for each representative image, the image was opened and a conversion scale applied by drawing a line over the scale bar and going to Analyze->Set Scale. The known distance and units were entered. The “Global” option was checked to set a global scale, which applied a size limit for particle analysis at a later step. Menu options Image-
  • the nonviable cells were either manually counted, or the foregoing procedure was repeated for red stains (i.e., 0-50 pass instead of 50-255 pass hue filter, 100-255 pass brightness filter, and 10-300um A 2 particle size). However, whenever possible, nonviable cells were manually counted because automated counts by IMAGEJ were known to sometimes return false positives because EthD-1 stains nuclei, not whole cells, and the stained nuclei are closer in size to non-cellular artifacts.
  • the % Viable Cells for each representative image was calculated as follows, which provides a snapshot look at cell viability in each sample at the time of enzymatic digestion:
  • AM+ and CMT refer to "Amnion” and “Chorion” with trophoblast layer, lyophilized as a bilayer, rehydrated for lOmin in PBS then peeled apart prior to testing as described
  • AM- and CM- refer to "Amnion” and “Chorion” without trophoblast layer, lyophilized as a bilayer, rehydrated for lOmin in PBS then peeled apart prior to testing as described ** Insufficient cells were recovered to perform counting of AM- digested cells for Iteration #6
  • Results of cell viability testing are provided in Tables 22 and 23 below, as a % of Week 0 ATP values.
  • CM+ reported average ATP values above 100%, most likely due to the highly variable nature of the metabolic activity of the placental tissue as well as variability in the trophoblast tissue layer thickness for each sample, which would impact the average cell density per tissue volume and thus the normalized nnmol of ATP/g of tissue.
  • Tissue was processed as described in Example 6 up through Step 20 (cutting 5cm x 5cm samples and placing each into a retainer in HBSS until all cutting was complete).
  • cryopreservation media Hyclone media with 10% DMSO
  • the samples and a representative probe sample were then cryopreserved using a controlled-rate freezer (Thermo Scientific CryoMed Model 7454) per the recipe provided in Table 24 below and stored then at -70°C or colder.
  • the lyopreserved samples contained about 20-30% of the ATP content of the corresponding cryopreserved samples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des échantillons de tissu conservés contenant des cellules viables endogènes et conservant ou favorisant une activité biologique après avoir été stockés à des températures au-dessus de la congélation pendant des périodes prolongées (par exemple, de 14 jours à 3 ans). Les échantillons de tissu conservés sont implantés dans ou sur un sujet et, après réhydratation, ils conservent une activité biologique bénéfique, favorisent une activité biologique bénéfique, ou les deux. L'activité biologique bénéfique comprend la promotion d'une ou de plusieurs propriétés parmi la cicatrisation tissulaire, la croissance tissulaire et la génération tissulaire. Des procédés de préparation des échantillons de tissu conservés comprennent la mise en contact d'un échantillon de tissu récupéré avec un ou plusieurs agents protecteurs, suivie d'une lyopréservation. Des agents protecteurs appropriés comprennent des sucres, des polyphénols, des caroténoïdes et des combinaisons de ceux-ci. Les agents protecteurs préférés comprennent le glucose, le fructose, le saccharose, le tréhalose, le dextrane, l'EGCG et des combinaisons de ceux-ci. L'échantillon de tissu récupéré peut être l'un quelconque de plusieurs types de problèmes possibles. Dans des modes de réalisation préférés, les échantillons de tissu récupérés sont choisis parmi l'os, le placenta, le cartilage et des combinaisons de ceux-ci.
PCT/US2020/065688 2019-12-17 2020-12-17 Formes de tissu viables et leurs procédés de fabrication et d'utilisation WO2021127230A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2020407094A AU2020407094A1 (en) 2019-12-17 2020-12-17 Viable tissue forms and methods for making and using same
US17/784,133 US20230044661A1 (en) 2019-12-17 2020-12-17 Viable tisssue forms and methods for making and using same
EP20848897.3A EP4076557A1 (fr) 2019-12-17 2020-12-17 Formes de tissu viables et leurs procédés de fabrication et d'utilisation
CA3165002A CA3165002A1 (fr) 2019-12-17 2020-12-17 Formes de tissu viables et leurs procedes de fabrication et d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962948905P 2019-12-17 2019-12-17
US62/948,905 2019-12-17

Publications (1)

Publication Number Publication Date
WO2021127230A1 true WO2021127230A1 (fr) 2021-06-24

Family

ID=74495006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/065688 WO2021127230A1 (fr) 2019-12-17 2020-12-17 Formes de tissu viables et leurs procédés de fabrication et d'utilisation

Country Status (4)

Country Link
EP (1) EP4076557A1 (fr)
AU (1) AU2020407094A1 (fr)
CA (1) CA3165002A1 (fr)
WO (1) WO2021127230A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024006351A3 (fr) * 2022-06-29 2024-02-15 Biostem Technologies, Inc. Allogreffes placentaires humaines stériles ayant une pluralité de fentes, d'ouvertures et/ou de fenêtres formées sur celles-ci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104282A1 (en) * 2016-06-24 2018-04-19 Osiris Therapeutics, Inc. Viable lyophilized compositions derived from human tissues and methods of making the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104282A1 (en) * 2016-06-24 2018-04-19 Osiris Therapeutics, Inc. Viable lyophilized compositions derived from human tissues and methods of making the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024006351A3 (fr) * 2022-06-29 2024-02-15 Biostem Technologies, Inc. Allogreffes placentaires humaines stériles ayant une pluralité de fentes, d'ouvertures et/ou de fenêtres formées sur celles-ci

Also Published As

Publication number Publication date
AU2020407094A1 (en) 2022-07-28
EP4076557A1 (fr) 2022-10-26
CA3165002A1 (fr) 2021-06-24

Similar Documents

Publication Publication Date Title
JP6964560B2 (ja) 骨移植片からなる微粉化組成物ならびにその製造および使用方法
US11471560B2 (en) Cancellous bone product including viable osteogenic cells
US20220372438A1 (en) Biologically functional soft tissue scaffolds and implants
JP5951172B2 (ja) 骨移植片組成物
JP6456829B2 (ja) 組織傷害および疾患を処置および予防するための組成物および方法
EP3193953B1 (fr) Produit de réparation osseuse et ses procédés d'utilisation
JP2015523153A (ja) 穿孔型軟骨製品
US20220202876A1 (en) Viable lyophilized compositions derived from human tissues and methods of making the same
KR20160147058A (ko) 치료적 태반 조성물, 이의 제조방법 및 사용방법
KR20200023438A (ko) 세포성 골 이식편 및 제조 및 사용 방법
JP2017531653A (ja) 胎盤組織の低温貯蔵のための方法および組成物
US20150258243A1 (en) Composition and method of preparation of bone allograft from endosteal portion of bone and isolated bone periosteum
AU2020407094A1 (en) Viable tissue forms and methods for making and using same
US20230044661A1 (en) Viable tisssue forms and methods for making and using same
US20160287752A1 (en) Reconstituted amniotic membrane-amniotic fluid combination tissue graft with standardized stem cell component and method of forming same
US20160287640A1 (en) Denuded amnion flowable tissue graft and method of forming same
US20220047774A1 (en) Decellularized muscle matrices and methods for making and using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20848897

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3165002

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020407094

Country of ref document: AU

Date of ref document: 20201217

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020848897

Country of ref document: EP

Effective date: 20220718